US20050239192A1 - Hybrid automated continuous nucleic acid and protein analyzer using real-time PCR and liquid bead arrays - Google Patents

Hybrid automated continuous nucleic acid and protein analyzer using real-time PCR and liquid bead arrays Download PDF

Info

Publication number
US20050239192A1
US20050239192A1 US11/159,008 US15900805A US2005239192A1 US 20050239192 A1 US20050239192 A1 US 20050239192A1 US 15900805 A US15900805 A US 15900805A US 2005239192 A1 US2005239192 A1 US 2005239192A1
Authority
US
United States
Prior art keywords
nucleic acid
flow cytometer
bead
acid assay
beads
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/159,008
Inventor
Shanavaz Nasarabadi
Richard Langlois
Billy Colston
Evan Skowronski
Fred Milanovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lawrence Livermore National Security LLC
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Priority to US11/159,008 priority Critical patent/US20050239192A1/en
Publication of US20050239192A1 publication Critical patent/US20050239192A1/en
Assigned to ENERGY, U.S. DEPARTMENT OF reassignment ENERGY, U.S. DEPARTMENT OF CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA reassignment THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NASARABADI, SHANAVAZ L., LANGLOIS, RICHARD G., MILANOVICH, FRED P., COLSTON JR., BILLY W., SKOWRONSKI, EVAN W.
Assigned to LAWRENCE LIVERMORE NATIONAL SECURITY, LLC reassignment LAWRENCE LIVERMORE NATIONAL SECURITY, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/02Devices for withdrawing samples
    • G01N1/22Devices for withdrawing samples in the gaseous state
    • G01N1/2202Devices for withdrawing samples in the gaseous state involving separation of sample components during sampling
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/08Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a stream of discrete samples flowing along a tube system, e.g. flow injection analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/02Devices for withdrawing samples
    • G01N1/22Devices for withdrawing samples in the gaseous state
    • G01N1/2202Devices for withdrawing samples in the gaseous state involving separation of sample components during sampling
    • G01N1/2211Devices for withdrawing samples in the gaseous state involving separation of sample components during sampling with cyclones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Electro-optical investigation, e.g. flow cytometers
    • G01N15/1456Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/02Devices for withdrawing samples
    • G01N1/22Devices for withdrawing samples in the gaseous state
    • G01N1/2202Devices for withdrawing samples in the gaseous state involving separation of sample components during sampling
    • G01N1/2214Devices for withdrawing samples in the gaseous state involving separation of sample components during sampling by sorption
    • G01N2001/2217Devices for withdrawing samples in the gaseous state involving separation of sample components during sampling by sorption using a liquid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Definitions

  • the present invention relates to an assay system and more particularly to a nucleic acid assay system.
  • microfabrication technologies are now well known and include sputtering, electrodeposition, low-pressure vapor deposition, photolithography, and etching. Microfabricated devices are usually formed on crystalline substrates, such as silicon and gallium arsenide, but may be formed on non-crystalline materials, such as glass or certain polymers.
  • crystalline devices can be precisely controlled since etched surfaces are generally crystal planes, and crystalline materials may be bonded by processes such as fusion at elevated temperatures, anodic bonding, or field-assisted methods.
  • Monolithic microfabrication technology now enables the production of electrical, mechanical, electromechanical, optical, chemical and thermal devices, including pumps, valves, heaters, mixers, and detectors for microliter to nanoliter quantities of gases, liquids, and solids.
  • optical waveguide probes and ultrasonic flexural-wave sensors can now be produced on a microscale. The integration of these microfabricated devices into a single system allows for the batch production of microscale reactor-based analytical instruments.
  • Such integrated microinstruments may be applied to biochemical, inorganic, or organic chemical reactions to perform biomedical and environmental diagnostics, as well as biotechnological processing and defection.
  • the operation of such integrated microinstruments is easily automated, and since the analysis can be performed in situ, contamination is very low. Because of the inherently small sizes of such devices, the heating and cooling can be extremely rapid. These devices have very low power requirement and can be powered by batteries or by electromagnetic, capacitive, inductive or optical coupling.
  • the small volumes and high surface-area to volume ratios of microfabricated reaction instruments provide a high level of control of the parameters of a reaction.
  • Heaters may produce temperature cycling or ramping; while sonochemical and sonophysical changes in conformational structures may be produced by ultrasound transducers; and polymerizations may be generated by incident optical radiation.
  • Synthesis reactions, and especially synthesis chain reactions such as the polymerase chain reaction (PCR) are particularly well-suited for microfabrication reaction instruments.
  • PCR can selectively amplify a single molecule of DNA (or RNA) of an organism by a factor of 10.sup.6 to 10.sup.9. This well-established procedure requires the repetition of heating (denaturing) and cooling (annealing) cycles in the presence of an original DNA target molecule, specific DNA primers, deoxynucleotide triphosphates, and DNA polymerase enzymes and cofactors.
  • the PCR procedure involves: 1) processing of the sample to release target DNA molecules into a crude extract; 2) addition of an aqueous solution containing enzymes, buffers deoxyribonucleotide triphosphates (dNTPS), and aligonucleotide primers; 3) thermal cycling of the reaction mixture between two or three temperatures (e.g., 90. degree.-96.degree., 72.degree., and 37.degree.-55.degree. C.); and 4) detection of amplified DNA.
  • Intermediate steps such as purification of the reaction products and the incorporation of surface-bending primers, for example, may be incorporated in the PCR procedure.
  • a problem with standard PCR laboratory techniques is that the PCR reactions may be contaminated or inhibited by the introduction of a single contaminant molecule of extraneous DNA, such as those from previous experiments, or other contaminants, during transfers of reagents from one vessel to another.
  • PCR reaction volumes used in standard laboratory techniques are typically on the order of 50 microliters.
  • a thermal cycle typically consists of four stages: heating a sample to a first temperature, maintaining the sample at the first temperature, cooling the sample to a second lower temperature, and maintaining the temperature at that lower temperature.
  • each of these four stages of a thermal cycle requires about one minute, and thus to complete forty cycles, for example, is about three hours.
  • the new environmental surveillance system uses monitoring technology and methods developed in part by the Department of Energy's national laboratories. Samples of DNA are analyzed using polymerase chain reaction techniques, which examine the genetic signatures of the organisms in a sample, and make rapid and accurate evaluations of that organism . . . . Officials who helped develop the system said that tests performed at Dugway Proving Ground in Utah and national laboratories showed that the system would almost certainly detect the deliberate release of several of the most dangerous pathogens. ‘Obviously, the larger the release, the greater the probability that the agent will be detected,’ an official said. ‘But given the coverage provided by the E.P.A. system, even a small release, depending on which way the wind was blowing and other meteorological conditions, is likely to be picked up.’”
  • Bio-Watch This technology is now expected to play a large role in the U.S. government's recently unveiled homeland security counter-terrorism initiative, Bio-Watch, which is designed to detect airborne bioterrorist attacks on major U.S. cities within hours. Announced back in January, Bio-Watch is a multi-faceted, multi-agency program that involves the U.S. Department of Energy, the Environmental Protection Agency (EPA), and the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention (CDC). Many of the EPA's 3,000 air-quality monitoring stations throughout the country are being adapted with biodetectors to register unusual quantities of a wide range of pathogens that cause diseases that incapacitate and kill, according to the EPA.
  • EPA Environmental Protection Agency
  • CDC U.S. Department of Health and Human Services' Centers for Disease Control and Prevention
  • the nationwide network of environmental monitors and biodetectors which reportedly will eventually monitor more than 120 U.S. cities, is expected to detect and report a biological attack within 24 hours. Citing security reasons, the EPA declined to disclose further details about the program at this time . . . .
  • the Autonomous Pathogen Detection System is a file-cabinet-sized machine that sucks in air, runs tests, and reports the results itself.
  • APDS integrates a flow cytometer and real-time PCR detector with sample collection, sample preparation, and fluidics to provide a compact, autonomously operating instrument capable of simultaneously detecting multiple pathogens and/or toxins.
  • APDS-II ‘The system is designed for fixed locations,’ says Langlois, ‘where it continuously monitors air samples and automatically reports the presence of specific biological agents.
  • APDS is targeted for domestic applications in which the public is at high risk of exposure to covert releases of bioagents—subway systems, transportation terminals, large office complexes, and convention centers . . . .
  • APDS provides the ability to measure up to 100 different agents and controls in a single sample,’ Langlois says. ‘It's being used in public buildings right now.’
  • the latest evolution of the biodetector, APDS-II uses bead-capture immunoassays and a compact flow cytometer for the simultaneous identification of multiple biological simulants. Laboratory tests have demonstrated the fully autonomous operation of APDS-II for as long as 24 hours.”
  • the present invention provides a hybrid nucleic acid assay system for analyzing a sample using a reagent comprising a thermal cycler, a sample and reagent delivery unit operatively connected to the thermal cycler for delivering the sample and the reagent to the thermal cycler, a hybridization chamber operatively connected to the thermal cycler, and a flow cytometer operatively connected to the hybridization chamber.
  • the present invention also provides a real time nucleic acid assay method for analyzing a sample using a reagent.
  • the method comprises the steps of providing a thermal cycler, providing a hybridization unit, providing a flow cytometer, transporting the sample and the reagent to said thermal cycler for amplification, and analyzing the sample with said flow cytometer utilize beads with each bead having a unique spectral address.
  • the hybrid nucleic acid analyzer system has many uses. For example, the hybrid nucleic acid analyzer system has use for clinical analysis of blood bank samples in a continuous 24/7 analysis of pathogens.
  • the hybrid nucleic acid analyzer system has use in diagnostic labs in hospitals for toxin, protein nucleic acid and assume analysis in clinical samples such as blood, saliva, urine, fecal matter, etc.
  • the hybrid nucleic acid analyzer system has uses as fly away lab or integrated into a continuous monitoring of environmental samples for detection of Biothreat agents.
  • the hybrid nucleic acid analyzer system also has use in automated processing, amplification and detection of biological molecules in forensic samples.
  • the hybrid nucleic acid analyzer system can also be used a point detector for automated clinical testing, analysis and archiving in event of an outbreak.
  • the hybrid nucleic acid analyzer system can also be used to detect proteins and toxins both in the clinic as well as from the environment.
  • FIG. 1 is a fluidic diagram of illustrates one embodiment of a hybrid nucleic acid analyzer constructed in accordance with the present invention.
  • FIG. 2 shows additional details of the reagent delivery system of the hybrid nucleic acid analyzer system illustrated in FIG. 1 .
  • FIG. 3 shows additional details of the thermal cycler of the hybrid nucleic acid analyzer system illustrated in FIG. 1 .
  • FIG. 4 shows additional details of the hybridization chamber of the hybrid nucleic acid analyzer system illustrated in FIG. 1 .
  • FIG. 5 shows schematics of the hybridization chamber illustrated in FIG. 4 .
  • FIG. 6 shows additional details of the flow cytometer of the hybrid nucleic acid analyzer system illustrated in FIG. 1 .
  • FIG. 7 shows the beads used in the hybridization chamber and the flow cytometer illustrated in FIG. 1 .
  • FIG. 8 illustrates how the beads are used in the hybridization chamber and the flow cytometer illustrated in FIG. 1 .
  • FIG. 9 provides additional information illustrating how the beads are used in the hybridization chamber and in the flow cytometer illustrated in FIG. 1 .
  • FIG. 10 illustrates how the beads are analyzed in the flow cytometer shown in FIG. 6 .
  • Nucleic acid amplification and detection is a widely used technique for conducting biological research. Utilization is applied to an increasing range of applications from diagnostics in bench-top research to the clinical arena, to genomic screening for drug discovery, to toxicology screening for contamination, to identification in a high throughput or conventional analysis capacity.
  • Conventional sample preparation and analysis techniques for performing nucleic acid assays are time-consuming, require trained technicians, and lack precise repeatability. New technical developments are needed to improve the performance of nucleic acid amplification and detection.
  • FIG. 1 a fluidic diagram of illustrates one embodiment of a hybrid nucleic acid analyzer constructed in accordance with the present invention.
  • This embodiment of the hybrid nucleic acid analyzer is designated generally by the reference numeral 100 .
  • Nucleic acid and protein analyses are usually done on separate analysis platforms.
  • Nucleic acid detection is conventionally done by either Real-time Taqman PCR detection or an end point electrophoresis.
  • Enzyme Linked Immuno assay (ELISA) is the method of choice for protein/antigen analysis.
  • the hybrid nucleic acid analyzer 100 provides a system for detecting and analyzing the samples: one based on PCR and the other based on flow cytometry.
  • the flow cytometry subsystem uses antibodies to identify pathogens.
  • small “capture” beads that are 5 micrometers in diameter are coated with antibodies specific to the target pathogens. The beads are color coded according to which antibodies they hold. Once the pathogens attach to their respective antibodies, more antibodies—those labeled with a fluorescent dye—are added to the mix. A labeled antibody will stick to its respective pathogen, creating a sort of bead sandwich-antibody, pathogen, and labeled antibody.
  • the beads flow one by one through a flow cytometer, which illuminates each bead in turn with a laser beam. Any bead with labeled antibodies will fluoresce. The system can then identify which agents are present, depending on the color of the capture bead.
  • the hybrid nucleic acid analyzer system 100 comprises a reagent delivery system 101 , a thermal cycler 102 , a hybridization chamber 103 , and a flow cytometer 104 .
  • the reagent delivery system 101 delivers PCR reagents to the thermal cycler 102 autonomously.
  • the reaction 5 ⁇ l is moved to the hybridization chamber 103 .
  • the 5 ⁇ l is mixed with 1e6 Luminex beads/ml in the hybridization chamber 103 for hybridization.
  • the hybridized beads are then moved to the flow cytometer 104 for analyses.
  • the hybrid nucleic acid analyzer system 100 utilizes nucleic acid amplification and detection and sample preparation and analysis techniques and information described in currently co-pending U.S. patent application Ser. Nos. 10/189,319 and 10/643,797, both of which are owed by the Regents of the University of California, the assignee of this application.
  • U.S. patent application Ser. No. 10/189,319 for an “Automated Nucleic Acid Assay System” was filed Jul. 2, 2002 by Billy W. Colston, Jr., Steve B. Brown, Shanavaz L. Nasarabadi, Phillip Belgrader, Fred Milanovich, Graham Marshall, Don Olson, and Duane Wolcott and was published as U.S. patent application No. 2003/0032172 on Feb.
  • a LabView interface software system controls the fluidic handling and the operation of the thermal cycler 102 .
  • the LabView interface software system software is integrated into a form compatible with the Graphical User Interface (GUI) used to control and monitor the flow cytometer 104 .
  • GUI Graphical User Interface
  • the reagent delivery system 101 includes a syringe pump 200 that delivers a carrier 201 to a holding coil 202 .
  • the carrier is available to a zone fluidics system.
  • the zone fluidics system provides sequential injection analysis (SIA).
  • Zone fluidics defines a general-purpose fluidics tool, allowing the precise manipulation of gases, liquids and solids to accomplish very complex analytical manipulations with relatively simple hardware.
  • Zone fluidics is the precisely controlled physical, chemical, and fluid-dynamic manipulation of zones of miscible and immiscible fluids in narrow bore conduits to accomplish sample conditioning and chemical analysis.
  • a zone is a volume region within a flow conduit containing at least one unique characteristic.
  • a unit operation in zone fluidics comprises of a set of fluid handling steps intended to contribute to the transformation of the sample into a detectable species or prepare it for manipulation in subsequent unit operations.
  • unit operations include sample filtering, dilution, enrichment, medium exchange, headspace sampling, solvent extraction, matrix elimination, de-bubbling, amplifying, hybridizing, and reacting.
  • sample filtering dilution, enrichment, medium exchange, headspace sampling, solvent extraction, matrix elimination, de-bubbling, amplifying, hybridizing, and reacting.
  • matrix elimination matrix elimination
  • de-bubbling amplifying, hybridizing, and reacting.
  • In current analytical practice many of these steps are handled manually or in isolated pieces of equipment. Integration is scant at best, and there is a high degree of analyst involvement.
  • zone fluidics sample and reagent zones are subjected to these unit operations in a sequential manner being transported from one unit operation to the next under fluidic control.
  • Zone fluidics provides an alternative approach whereby unit operations are performed in narrow bore conduits and the transportation medium, instead of being mechanical as in robotics, is fluidic.
  • a zone fluidics manifold At the heart of a zone fluidics manifold is a multi-position selection valve. Fluids are propelled and manipulated in the manifold by means of a bi-directional flow pump. A holding coil between the pump and valve is used to stack zones and mix adjacent zones through dispersion and diffusion as is practiced in sequential injection analysis (SIA).
  • SIA sequential injection analysis
  • the ports of the multi-position valve are coupled to various reservoirs, reactors, manifold devices, and detectors as indicated.
  • Narrow bore conduits comprise the flow channels and provide fluid contact between manifold devices and components.
  • fluid refers to liquids, gases, aerosols, and suspensions. Samples in zone fluidics are not limited to liquids. Rather, gases, and suspensions containing solids or cells are also included. Where solid samples are used, particles are limited to a size that ensures no blockages.
  • reagents are prepared and then coupled to the zone fluidics manifold.
  • the metering capability of the pump and mixing unit operations allow for reagents and standards to be prepared in situ.
  • Reagents can therefore be presented to the zone fluidics manifold in an appropriately designed cartridge as ready-made, reagent concentrates, lyophilized, or crystalline form.
  • Standards can be plumbed to the multi-position valve as discrete reservoirs providing the required range of concentrations.
  • standards can also be prepared in situ or diluted to cover a larger dynamic range.
  • a syringe pump 200 delivers a carrier 201 to a holding coil 202 .
  • the carrier is available to a zone fluidics system.
  • the zone fluidics system provides in sequential injection analysis (SIA).
  • the ports of a multi-position valve 203 of the zone fluidics sequential injection analysis system are coupled to air reservoir 204 , negative reservoir 205 , field sample reservoir 206 , reagent reservoir 207 , plug 208 , waste 209 , bleach reservoir 210 , and bleach reservoir 211 as indicated.
  • the zone fluidics sequential injection analysis system has an outlet 212 that delivers PCR reagents to the thermal cycler 102 .
  • thermal cycler 102 of the hybrid nucleic acid analyzer system 100 of the present invention details of the thermal cycler 102 of the hybrid nucleic acid analyzer system 100 of the present invention are shown.
  • PCR Polymerase Chain Reaction
  • Some examples of commercially available semi-portable instruments include the iCycler manufactured by Bio-Rad, the Light cycler from Idaho Technologies and the Smart Cycler from Cepheid Inc.
  • Real-time PCR works by including in a reaction mix sequence specific oligonucleotides (primer) that can be extended at its 3′ end and a third non-extendable oligonucleotide (probe) that has two fluorescence molecules attached to its 5′ and 3′ end respectively.
  • FRET Fluorescence Resonance Energy Transfer
  • the enzyme DNA polymerase has 5′-3′ exo-nuclease activity as well as 5′-3′ polymerase activity.
  • primer extension the fluorophore is cleaved from the 5′ end of the probe and since the fluorophore is no longer quenched, a signal is detected by the fluorimeter.
  • These instruments are designed for measuring the fluorescence released from sequence specific probes in case of a positive identification. At present the multiplexing of nucleic acid signatures is limited by the number of fluorophores that can be used in the commercial instruments, due to spectral overlap of most of these fluorophores.
  • the thermal cycler 102 of the present invention can be a unit such as that described in U.S. Pat. No. 5,589,136 issued Dec. 31, 1996 to M. Allen Northrup, Raymond P. Mariella, Jr., Anthony V. Carrano, and Joseph W. Balch and assigned to the Regents of the University of California or in U.S. Pat. No. 6,586,233 issued Jul. 1, 2003 to William J. Benett. James B. Richards, and Fred P. Milanovich and assigned to the Regents of the University of California.
  • the disclosures of U.S. Pat. No. 5,589,136 issued Dec. 31, 1996 and U.S. Pat. No. 6,586,233 issued Jul. 1, 2003 are incorporated herein by this reference. As show in FIG.
  • a chamber unit 300 is fabricated of circuit board material.
  • the system can be constructed of materials such as circuit board fiberglass, silicon, ceramics, metal, or glass. Advantages of using circuit board fiberglass is the fact that it is not as thermally conductive as the other materials and the heating is more efficiently applied to the sample rather than being conducted to surrounding materials. Circuit board material is readily available and the technology of producing and working with circuit board material is highly developed. Circuit board material provides lower cost techniques for fabrication. Printed circuit board technology incorporates photolithography, metal etching, numerically controlled machining, and layering technologies to produce the desired device.
  • the thermal cycler 102 is generally indicated at 300 .
  • the thermal cycler 102 includes a silicon-based sleeve as a chemical reaction chamber, generally indicated at 301 , constructed of two bonded silicon parts, and which utilizes doped polysilicon for heating and bulk silicon for convective cooling, as described in greater detail hereinafter.
  • the sleeve 301 includes a slot or opening 304 into which reaction fluid, indicated at 306 , from a conduit 305 is inserted into the reaction chamber.
  • the conduit 305 is constructed of plastic, for example, or other material which is inert with respect to the reaction mixture, thereby alleviating any potential material incompatibility issues.
  • the sleeve is also provided with an opening 302 in which is located an optical window 303 , made, for example, of silicon nitride, silicon dioxide, or polymers.
  • the silicon sleeve reaction chamber 301 includes doped polysilicon for heating and bulk silicon for convective cooling, and combines a critical ratio of silicon and silicon nitride to the volume of material to be heated (e.g., liquid) in order to provide uniform heating, yet low power requirements.
  • the thermal cycler 102 can be used to rapidly and repetitively provide controlled thermal cycles to the reaction mixture.
  • the thermal conductivity properties of the silicon or similar semiconducting substrate help speed up the thermal rise and fall times, and allow low power operation. While silicon is unique in its thermal properties, i.e., high thermal conductivity, a combination of silicon, silicon nitride, silicon dioxide, polymers and other materials would provide a combination of thermal conductivity and insulation that would allow thermal uniformity and low power operation.
  • the Sample and the nucleic acid reaction mix are introduced into the thermal cycler 102 by the Sequential Injection Analysis fluid handling system illustrated in FIG. 2 .
  • the sample is continuously driven by convection through the channels it passes through sections of channel that are temperature controlled to be at the upper and lower temperatures required for the PCR reaction. This continuous flow through the PCR temperature zones effectively thermally cycles the sample.
  • hybridization chamber 103 uses a simple copper coil around the reaction chamber to heat the bead and PCR mixture to the denaturation temperature.
  • the chamber After denaturation, the chamber is brought to its hybridization temperature of 55-60° C. with a fan placed at the bottom of the unit.
  • the multi-position valve 400 delivers the beads and sample to the bead trap 410 and to a multi-position valve 411 .
  • the multi-position valve 411 is coupled to air reservoir 412 , plug 413 , Cal beads 414 , and waste 415 as indicated.
  • the hybridization chamber 103 has an outlet 416 that delivers the hybridized sample to the flow cytometer 104 .
  • a copper tube support 500 provides a support for the hybridization chamber 103 and its associated equipment.
  • the hybridization chamber 103 includes a temperature control sensor 501 , heatshrink insulation 502 , a muffin fan 503 , a foil heater 504 , tubing 505 , and a fan 506 .
  • the heater 504 heats the chamber to the denaturation temperature of 95° C. followed by a cooling to the required hybridization temperature with the aid of the fans 503 and 506 .
  • the PID temperature control sensor 501 precisely monitors the denaturation and hybridization temperatures within a couple of degrees.
  • the hybridization chamber 103 provides a single step movement of hybridization reagents into the chamber.
  • the amplified mix is hybridized to luminex beads in-line before being sent to the Flow Cytometer 104 for analysis.
  • the hybridization chamber 103 heats the bead and PCR mixture to the denaturation chamber. After denaturation, the chamber is brought to its hybridization temperature of 55-60° C. with the fans 503 and 506 .
  • the hybridization chamber 103 has an outlet that delivers the hybridized sample to the flow cytometer 104 .
  • the flow cytometer 104 comprises a Luminex LX100 Flow Cytometer instrument 600 with a sheath source 601 and a waste reservoir 602 .
  • the hybridized bead array is from the hybridization camber 103 is introduced into the Luminex Flow Cytometer instrument 600 where the beads are interrogated by two lasers, a red laser for the internal discriminator and a green laser for the external discriminator dyes respectively. Additional details of the flow cytometer 600 and its operation are show in FIGS. 7, 8 , 9 , and 10 .
  • the protein (toxin or antigen) assay on the liquid bead arrays is a typical sandwich assay.
  • the antibody specific to the antigen or a toxin is attached to the surface of Carboxylated polystyrene beads described above.
  • the antigen is then hybridized to the bead sets followed by a secondary antibody to which is attached the secondary discriminator phycoerythrin.
  • Luminex Bead based Array analyzer In order to multiplex more than four signatures, Applicants have designed a Luminex Bead based Array analyzer. With the liquid arrays it is possible to multiplex over 100 different organisms. The discrimination of the polystyrene Luminex bead array is dependent on the precise ratio of two internal discriminator dyes, a red and an infrared dye. The signal intensity on the surface of the bead is dependent on the concentration of the analyte in solution, in our case the amplified DNA of a suspect agent or an antigen or a toxin, whichever the case may be.
  • a 100-plex Luminex liquid array 700 is generated by intercalating varying ratios of red and orange infrared dyes into polystyrene latex microspheres or beads 701 .
  • the process of producing varying ratios of red and orange infrared dyes in the beads 701 is accomplished by increasing the amount of red dye as illustrated by the arrow 702 and increasing the amount of orange dye as illustrated by the arrow 703 . This gives each optically encoded bead 700 a unique spectral address.
  • the beads designated by the reference numeral 800 are coated with capture antibodies specific for target antigens.
  • Each bead has an attachment site specific for a bioagent.
  • the upper bead has an attachment site 801 for anthrax.
  • the next bead has an attachment site 802 for plague.
  • the next bead has an attachment site 803 for small pox.
  • the next bead has an attachment site 804 for botox.
  • the attachment site 801 for anthrax attaches to the anthrax bioagent 805 .
  • the attachment site 802 for plague attaches to the plague bioagent 806 .
  • the attachment site 803 for small pox attaches to the small pox bioagent 807 .
  • the attachment site 804 for botox attaches to the botox bioagent 808 .
  • secondary or detector antibodies are added, followed by addition of the fluorescent reporter, phycoerythrin 809 to complete the “antigen sandwich.”
  • FIG. 9 additional information is provided illustrating how the beads are used in the hybridization chamber 103 and in the flow cytometer 104 .
  • the beads are designated by the reference numeral 900 .
  • FIG. 9 illustrates bead hybridization with amplified PCR product.
  • the PCR product 901 is added to labeled luminex bead mix and denatured. This is followed by hybridization and addition of SA-PE 902 .
  • the hybridized beads are then detected in the Luminex flow cytometer 104 .
  • FIG. 10 an illustration shows how the beads are analyzed in the flow cytometer.
  • the beads are designated by the reference numeral 1000 .
  • the direction of flow is shown by the arrow 1001 .
  • the beads 1000 are interrogated one at a time. As illustrated, one bead 1000 is shown being interrogated.
  • a red laser classifies the bead 1000 , identifying the bead type.
  • a green laser 1002 quantifies the assay on the bead surface—only those beads with a complete sandwich will produce a fluoresce 1003 in the green, and the signal is a function of antigen concentration.
  • the hybrid nucleic acid analyzer provides an integrated nucleic acid and protein/toxin detection system capable of in-line analysis of a complex sample within an hour or less.
  • the rate limiting step is the rapidity with which the nucleic acid is amplified, the hybridization being instantaneous.
  • the hybrid nucleic acid analyzer has the capability of performing continuous nucleic acid and immunoassays in a multiplex format.
  • the hybrid nucleic acid analyzer is a field deployable instrument for detection of pathogens and toxins in environmental or clinical samples.
  • the hybrid nucleic acid analyzer takes advantage of the multiplexing capability of the Luminex Bead arrays complexed with multiplexed nucleic acid and protein capability developed at the Lawrence Livermore National Laboratory.
  • the hybrid nucleic acid analyzer has an integrated PCR chamber 102 , DNA Hybridization chamber 103 , and Luminex LX100 flow cytometer 104 controlled by a LabView interface software for the fluidic handling and the operation of the PCR chamber.
  • the software is integrated into a form compatible with the Graphical User Interface (GUI) used to control and monitor the Luminex LX100 flow cytometer.
  • GUI Graphical User Interface
  • Control and data analysis software routines have been written for controlling the Luminex LX100 flow cytometry. Provisions have been made for the addition of a sample preparation and concentration unit as well as a bead sequestering unit in order to facilitate deep multiplexing of the agents.
  • a sample preparation and concentration strategy involves the use of Silicon pillar chips capable of handling volumes of up to 100 ml or more of the sample, releasing the DNA from the cells through lysis and concentrating it in a small volume for analysis, thus increasing the detection limit many folds.
  • the fluidics in the instrument is self-contained in order to minimize contamination of the surroundings and the operator. This minimizes contamination of reagents and samples, a feature not available in commercial units.
  • the sample and the nucleic acid reaction mix are introduced into the thermal cycler 102 by Sequential Injection Analysis fluid handling system 101 .
  • the hybridization chamber 103 uses a simple copper coil around the reaction chamber to heat the bead and PCR mixture to the denaturation chamber. After denaturation, the chamber is brought to its hybridization temperature of 55-60° C. with a fan placed at the bottom of the unit.
  • a thermocouple inserted in the housing of the hybridization chamber as well as on the silicon sleeve of the thermal cycling chamber is used to control the temperatures via feed back from a PID controller. In this instrument the reagents are pre-loaded onto the system so that there is minimal user interface.
  • the detection is autonomously done following the sequence of events input by the researcher.
  • Decontamination of the fluidics system is carried out autonomously after each amplification step.
  • the system including the PCR chamber 102 , the hybridization chamber 103 , the tubing carrying the sample to the PCR chamber and all the tubing and fitting downstream from there on are rinsed with 5% household bleach which we have found sufficient to effectively remove all traces of nucleic acids or PCR product from the housing.
  • a negative control for the agent/agents is amplified in order to determine the efficacy of the decontamination process.
  • Manual labor is the major factor for the high cost of sample testing.
  • the software has the capability of stacking a series of fluidic protocols for autonomous analysis.
  • the instrument 100 can be loaded with the reagents and the samples at the beginning of the day and the results can be accessed from a remote location. This cuts the cost of labor as compared to the conventional way of doing analysis.
  • this instrument it is possible to perform continuous analysis of samples from a known set of reagents with minimal intervention in effect significantly reducing the cost of the assay.
  • the hybrid nucleic acid analyzer 100 provides autonomous use of both the thermal cycler 102 and the flow cytometer 104 such that protein analysis can be performed independent of the nucleic acid detection.
  • the sample is introduced directly to appropriately labeled beads followed by hybridization to the secondary antibody and analysis of the assay in the flow cytometer 104 .
  • the hybrid nucleic acid analyzer 100 can be repeatedly decontaminated in between runs with a solution of 5% household bleach.
  • the nucleic acid detection is done by hybridization of the amplified PCR product with the probes attached to the surface of the bead sets via NHS ester linkage chemistry.
  • the PCR product is labeled with Biotin molecules and the hybridization of the product to the beads is followed by streptavidin phycoerythrin addition to the hybridized reaction mix.
  • the hybrid nucleic acid analyzer system 100 provides a closed integrated rapid Real-time PCR and multiplex flow analysis instrument for identification of multiplex pathogen and toxin within an hour with minimal exposure to the technician.
  • the hybrid nucleic acid analyzer system 100 combines Real-time flow through PCR with an inline flow cytometer to detect both nucleic acids as well as proteins.
  • Sequential injection analysis (SIA) fluidic system is used to deliver the sample and reagent for in-line mixing, analysis and archiving of samples.
  • SIA Sequential injection analysis
  • the unused PCR reaction mix is moved to the waste stream.
  • the hybrid system is decontaminated and made ready for another round of amplification by rinsing with a 5% solution of Household Bleach followed by water rinse.
  • a negative reaction with water substituted for sample is run between sample amplifications to ensure that the system is free of carry over PCR product.
  • the hybrid nucleic acid analyzer 100 has many uses. For example, the system 100 has use for clinical analysis of blood bank samples in a continuous 24/7 analysis of pathogens. The system 100 has use in diagnostic labs. The system 100 has use as a fly away lab or integrated into continuous monitoring of environmental samples for detection of Biothreat agents. The system 100 also has use in automated processing, amplification and detection of biological molecules in forensic samples. The system 100 can also be used for automated clinical testing, analysis and archiving in event of an outbreak. The system 100 can also be used to detect proteins and toxins both in the clinic as well as from the environment.

Abstract

A nucleic acid assay system for analyzing a sample using a reagent. A sample and reagent delivery unit is operatively connected to a thermal cycler for delivering the sample and the reagent to the thermal cycler. A hybridization chamber is operatively connected to the thermal cycler. A flow cytometer is operatively connected to the hybridization chamber.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a Continuation-in-Part of co-pending U.S. patent application Ser. No. 10/643,797 filed Aug. 19, 2003 and titled, “System for Autonomous Monitoring of Bioagents.” U.S. patent application Ser. No. 10/643,797 filed Aug. 19, 2003 claims the benefit of U.S. Provisional Patent Application No. 60/406,159 filed Aug. 26, 2002. U.S. patent application Ser. No. 10/643,797 filed Aug. 19, 2003 and U.S. Provisional Patent Application No. 60/406,159 filed Aug. 26, 2002 are incorporated herein by this reference.
  • The United States Government has rights in this invention pursuant to Contract No. W-7405-ENG-48 between the United States Department of Energy and the University of California for the operation of Lawrence Livermore National Laboratory.
  • BACKGROUND
  • 1. Field of Endeavor
  • The present invention relates to an assay system and more particularly to a nucleic acid assay system.
  • 2. State of Technology
  • U.S. Pat. No. 4,022,575 for an automatic chemical analyzer to Elo H. Hansen and Jaromir Ruzicka issued May 10, 1977 provide the following background information, “The ever increasing demand for numbers of analyses in clinical, agricultural, pharmaceutical and other types of analytical control has lead to the development of a large number of various instruments for automated analysis. The development in this field is further being stimulated by the additional advantages gained by automation: increased precision, decreased cost per assay and good reliability of the automated equipment.”
  • U.S. Pat. No. 5,589,136 for silicon-based sleeve devices for chemical reactions, assigned to the Regents of the University of California, inventors: M. Allen Northrup, Raymond P. Mariella, Jr., Anthony V. Carrano, and Joseph W. Balch, patented Dec. 31, 1996 provides the following background information: “Current instruments for performing chemical synthesis through thermal control and cycling are generally very large (table-top) and inefficient, and often they work by heating and cooling of a large thermal mass (e.g., an aluminum block). In recent years efforts have been directed to miniaturization of these instruments by designing and constructing reaction chambers out of silicon and silicon-based materials (e.g., silicon, nitride, polycrystalline silicon) that have integrated heaters and cooling via convection through the silicon. Microfabrication technologies are now well known and include sputtering, electrodeposition, low-pressure vapor deposition, photolithography, and etching. Microfabricated devices are usually formed on crystalline substrates, such as silicon and gallium arsenide, but may be formed on non-crystalline materials, such as glass or certain polymers. The shapes of crystalline devices can be precisely controlled since etched surfaces are generally crystal planes, and crystalline materials may be bonded by processes such as fusion at elevated temperatures, anodic bonding, or field-assisted methods. Monolithic microfabrication technology now enables the production of electrical, mechanical, electromechanical, optical, chemical and thermal devices, including pumps, valves, heaters, mixers, and detectors for microliter to nanoliter quantities of gases, liquids, and solids. Also, optical waveguide probes and ultrasonic flexural-wave sensors can now be produced on a microscale. The integration of these microfabricated devices into a single system allows for the batch production of microscale reactor-based analytical instruments. Such integrated microinstruments may be applied to biochemical, inorganic, or organic chemical reactions to perform biomedical and environmental diagnostics, as well as biotechnological processing and defection. The operation of such integrated microinstruments is easily automated, and since the analysis can be performed in situ, contamination is very low. Because of the inherently small sizes of such devices, the heating and cooling can be extremely rapid. These devices have very low power requirement and can be powered by batteries or by electromagnetic, capacitive, inductive or optical coupling. The small volumes and high surface-area to volume ratios of microfabricated reaction instruments provide a high level of control of the parameters of a reaction. Heaters may produce temperature cycling or ramping; while sonochemical and sonophysical changes in conformational structures may be produced by ultrasound transducers; and polymerizations may be generated by incident optical radiation. Synthesis reactions, and especially synthesis chain reactions such as the polymerase chain reaction (PCR), are particularly well-suited for microfabrication reaction instruments. PCR can selectively amplify a single molecule of DNA (or RNA) of an organism by a factor of 10.sup.6 to 10.sup.9. This well-established procedure requires the repetition of heating (denaturing) and cooling (annealing) cycles in the presence of an original DNA target molecule, specific DNA primers, deoxynucleotide triphosphates, and DNA polymerase enzymes and cofactors. Each cycle produces a doubling of the target DNA sequence, leading to an exponential accumulation of the target sequence. The PCR procedure involves: 1) processing of the sample to release target DNA molecules into a crude extract; 2) addition of an aqueous solution containing enzymes, buffers deoxyribonucleotide triphosphates (dNTPS), and aligonucleotide primers; 3) thermal cycling of the reaction mixture between two or three temperatures (e.g., 90. degree.-96.degree., 72.degree., and 37.degree.-55.degree. C.); and 4) detection of amplified DNA. Intermediate steps, such as purification of the reaction products and the incorporation of surface-bending primers, for example, may be incorporated in the PCR procedure. A problem with standard PCR laboratory techniques is that the PCR reactions may be contaminated or inhibited by the introduction of a single contaminant molecule of extraneous DNA, such as those from previous experiments, or other contaminants, during transfers of reagents from one vessel to another. Also, PCR reaction volumes used in standard laboratory techniques are typically on the order of 50 microliters. A thermal cycle typically consists of four stages: heating a sample to a first temperature, maintaining the sample at the first temperature, cooling the sample to a second lower temperature, and maintaining the temperature at that lower temperature. Typically, each of these four stages of a thermal cycle requires about one minute, and thus to complete forty cycles, for example, is about three hours. Thus, due to the large volume typically used in standard laboratory procedures, the time involved, as well as the contamination possibilities during transfers of reagents from one vessel to another, there is clearly a need for microinstruments capable of carrying out the PCR procedure.”
  • In an article titled, “U.S. Is Deploying a Monitor System for Germ Attacks,” by Judith Miller in The New York Times on Jan. 22, 2003, it was reported, “To help protect against the threat of bioterrorism, the Bush administration on Wednesday will start deploying a national system of environmental monitors that is intended to tell within 24 hours whether anthrax, smallpox and other deadly germs have been released into the air, senior administration officials said today. The system uses advanced data analysis that officials said had been quietly adapted since the September 11 attacks and tested over the past nine months. It will adapt many of the Environmental Protection Agency's 3,000 air quality monitoring stations throughout the country to register unusual quantities of a wide range of pathogens that cause diseases that incapacitate and kill . . . . The new environmental surveillance system uses monitoring technology and methods developed in part by the Department of Energy's national laboratories. Samples of DNA are analyzed using polymerase chain reaction techniques, which examine the genetic signatures of the organisms in a sample, and make rapid and accurate evaluations of that organism . . . . Officials who helped develop the system said that tests performed at Dugway Proving Ground in Utah and national laboratories showed that the system would almost certainly detect the deliberate release of several of the most dangerous pathogens. ‘Obviously, the larger the release, the greater the probability that the agent will be detected,’ an official said. ‘But given the coverage provided by the E.P.A. system, even a small release, depending on which way the wind was blowing and other meteorological conditions, is likely to be picked up.’”
  • In an article titled, “Biodetectors Evolving, Monitoring U.S. Cities,” by Sally Cole in the May 2003 issue of Homeland Security Solutions, it was reported, “The anthrax letter attacks of 2001, and subsequent deaths of five people, brought home the reality of bioterrorism to Americans and provided a wake-up call for the U.S. government about the need for a method to detect and mitigate the impact of any such future attacks. Long before the anthrax letter attacks, scientists at two of the U.S. Department of Energy's national laboratories, Lawrence Livermore National Laboratory (LLNL) and Los Alamos National Laboratory (LANL), were busy pioneering a “biodetector” akin to a smoke detector to rapidly detect the criminal use of biological agents. This technology is now expected to play a large role in the U.S. government's recently unveiled homeland security counter-terrorism initiative, Bio-Watch, which is designed to detect airborne bioterrorist attacks on major U.S. cities within hours. Announced back in January, Bio-Watch is a multi-faceted, multi-agency program that involves the U.S. Department of Energy, the Environmental Protection Agency (EPA), and the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention (CDC). Many of the EPA's 3,000 air-quality monitoring stations throughout the country are being adapted with biodetectors to register unusual quantities of a wide range of pathogens that cause diseases that incapacitate and kill, according to the EPA. The nationwide network of environmental monitors and biodetectors, which reportedly will eventually monitor more than 120 U.S. cities, is expected to detect and report a biological attack within 24 hours. Citing security reasons, the EPA declined to disclose further details about the program at this time . . . . The Autonomous Pathogen Detection System (APDS) is a file-cabinet-sized machine that sucks in air, runs tests, and reports the results itself. APDS integrates a flow cytometer and real-time PCR detector with sample collection, sample preparation, and fluidics to provide a compact, autonomously operating instrument capable of simultaneously detecting multiple pathogens and/or toxins. ‘The system is designed for fixed locations,’ says Langlois, ‘where it continuously monitors air samples and automatically reports the presence of specific biological agents. APDS is targeted for domestic applications in which the public is at high risk of exposure to covert releases of bioagents—subway systems, transportation terminals, large office complexes, and convention centers . . . . APDS provides the ability to measure up to 100 different agents and controls in a single sample,’ Langlois says. ‘It's being used in public buildings right now.’ The latest evolution of the biodetector, APDS-II, uses bead-capture immunoassays and a compact flow cytometer for the simultaneous identification of multiple biological simulants. Laboratory tests have demonstrated the fully autonomous operation of APDS-II for as long as 24 hours.”
  • SUMMARY
  • Features and advantages of the present invention will become apparent from the following description. Applicants are providing this description, which includes drawings and examples of specific embodiments, to give a broad representation of the invention. Various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this description and by practice of the invention. The scope of the invention is not intended to be limited to the particular forms disclosed and the invention covers all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the claims.
  • The present invention provides a hybrid nucleic acid assay system for analyzing a sample using a reagent comprising a thermal cycler, a sample and reagent delivery unit operatively connected to the thermal cycler for delivering the sample and the reagent to the thermal cycler, a hybridization chamber operatively connected to the thermal cycler, and a flow cytometer operatively connected to the hybridization chamber. The present invention also provides a real time nucleic acid assay method for analyzing a sample using a reagent. The method comprises the steps of providing a thermal cycler, providing a hybridization unit, providing a flow cytometer, transporting the sample and the reagent to said thermal cycler for amplification, and analyzing the sample with said flow cytometer utilize beads with each bead having a unique spectral address.
  • The hybrid nucleic acid analyzer system has many uses. For example, the hybrid nucleic acid analyzer system has use for clinical analysis of blood bank samples in a continuous 24/7 analysis of pathogens. The hybrid nucleic acid analyzer system has use in diagnostic labs in hospitals for toxin, protein nucleic acid and ménage analysis in clinical samples such as blood, saliva, urine, fecal matter, etc. The hybrid nucleic acid analyzer system has uses as fly away lab or integrated into a continuous monitoring of environmental samples for detection of Biothreat agents. The hybrid nucleic acid analyzer system also has use in automated processing, amplification and detection of biological molecules in forensic samples. The hybrid nucleic acid analyzer system can also be used a point detector for automated clinical testing, analysis and archiving in event of an outbreak. The hybrid nucleic acid analyzer system can also be used to detect proteins and toxins both in the clinic as well as from the environment.
  • The invention is susceptible to modifications and alternative forms. Specific embodiments are shown by way of example. It is to be understood that the invention is not limited to the particular forms disclosed. The invention covers all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the claims.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The accompanying drawings, which are incorporated into and constitute a part of the specification, illustrate specific embodiments of the invention and, together with the general description of the invention given above, and the detailed description of the specific embodiments, serve to explain the principles of the invention.
  • FIG. 1 is a fluidic diagram of illustrates one embodiment of a hybrid nucleic acid analyzer constructed in accordance with the present invention.
  • FIG. 2 shows additional details of the reagent delivery system of the hybrid nucleic acid analyzer system illustrated in FIG. 1.
  • FIG. 3 shows additional details of the thermal cycler of the hybrid nucleic acid analyzer system illustrated in FIG. 1.
  • FIG. 4 shows additional details of the hybridization chamber of the hybrid nucleic acid analyzer system illustrated in FIG. 1.
  • FIG. 5 shows schematics of the hybridization chamber illustrated in FIG. 4.
  • FIG. 6 shows additional details of the flow cytometer of the hybrid nucleic acid analyzer system illustrated in FIG. 1.
  • FIG. 7 shows the beads used in the hybridization chamber and the flow cytometer illustrated in FIG. 1.
  • FIG. 8 illustrates how the beads are used in the hybridization chamber and the flow cytometer illustrated in FIG. 1.
  • FIG. 9 provides additional information illustrating how the beads are used in the hybridization chamber and in the flow cytometer illustrated in FIG. 1.
  • FIG. 10 illustrates how the beads are analyzed in the flow cytometer shown in FIG. 6.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Referring to the drawings, to the following detailed description, and to incorporated materials, detailed information about the invention is provided including the description of specific embodiments. The detailed description serves to explain the principles of the invention. The invention is susceptible to modifications and alternative forms. The invention is not limited to the particular forms disclosed. The invention covers all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the claims.
  • Nucleic acid amplification and detection is a widely used technique for conducting biological research. Utilization is applied to an increasing range of applications from diagnostics in bench-top research to the clinical arena, to genomic screening for drug discovery, to toxicology screening for contamination, to identification in a high throughput or conventional analysis capacity. Conventional sample preparation and analysis techniques for performing nucleic acid assays are time-consuming, require trained technicians, and lack precise repeatability. New technical developments are needed to improve the performance of nucleic acid amplification and detection.
  • Early attempts to automate analytical science turned to robotics, but the high cost of instrumentation and excessive complexity demanded large budgets both in terms of hardware and research effort. With the rapid growth in genomics, and proteomics, and high throughput screening techniques, robotics has enjoyed resurgence. The requirement for large hardware budgets and research resources has not changed.
  • Referring now to FIG. 1, a fluidic diagram of illustrates one embodiment of a hybrid nucleic acid analyzer constructed in accordance with the present invention. This embodiment of the hybrid nucleic acid analyzer is designated generally by the reference numeral 100. Nucleic acid and protein analyses are usually done on separate analysis platforms. Nucleic acid detection is conventionally done by either Real-time Taqman PCR detection or an end point electrophoresis. Enzyme Linked Immuno assay (ELISA) is the method of choice for protein/antigen analysis.
  • One embodiment of the hybrid nucleic acid analyzer 100 provides a system for detecting and analyzing the samples: one based on PCR and the other based on flow cytometry. The flow cytometry subsystem uses antibodies to identify pathogens. For the flow-cytometry subsystem, small “capture” beads that are 5 micrometers in diameter are coated with antibodies specific to the target pathogens. The beads are color coded according to which antibodies they hold. Once the pathogens attach to their respective antibodies, more antibodies—those labeled with a fluorescent dye—are added to the mix. A labeled antibody will stick to its respective pathogen, creating a sort of bead sandwich-antibody, pathogen, and labeled antibody. The beads flow one by one through a flow cytometer, which illuminates each bead in turn with a laser beam. Any bead with labeled antibodies will fluoresce. The system can then identify which agents are present, depending on the color of the capture bead.
  • The hybrid nucleic acid analyzer system 100 comprises a reagent delivery system 101, a thermal cycler 102, a hybridization chamber 103, and a flow cytometer 104. The reagent delivery system 101 delivers PCR reagents to the thermal cycler 102 autonomously. On completion of cycling in the thermal cycler 102, the reaction 5 μl is moved to the hybridization chamber 103. The 5 μl is mixed with 1e6 Luminex beads/ml in the hybridization chamber 103 for hybridization. The hybridized beads are then moved to the flow cytometer 104 for analyses.
  • The hybrid nucleic acid analyzer system 100 utilizes nucleic acid amplification and detection and sample preparation and analysis techniques and information described in currently co-pending U.S. patent application Ser. Nos. 10/189,319 and 10/643,797, both of which are owed by the Regents of the University of California, the assignee of this application. U.S. patent application Ser. No. 10/189,319 for an “Automated Nucleic Acid Assay System” was filed Jul. 2, 2002 by Billy W. Colston, Jr., Steve B. Brown, Shanavaz L. Nasarabadi, Phillip Belgrader, Fred Milanovich, Graham Marshall, Don Olson, and Duane Wolcott and was published as U.S. patent application No. 2003/0032172 on Feb. 13, 2003. U.S. patent application Ser. No. 10/643,797 for a “System for Autonomous Monitoring of Bioagents” was filed Aug. 19, 2003 by Richard G. Langlois, Fred Milanovich, Billy W. Colston, Jr., Steve B. Brown, Don A. Masquelier, Ray P. Mariella, and Kodomundi Venkateswaran and was published as U.S. patent application No. 2004/0038385 on Feb. 26, 2004. The disclosures of U.S. patent application Ser. Nos. 10/189,319 and 10/643,797 are incorporated herein by this reference.
  • A LabView interface software system controls the fluidic handling and the operation of the thermal cycler 102. The LabView interface software system software is integrated into a form compatible with the Graphical User Interface (GUI) used to control and monitor the flow cytometer 104.
  • Referring now to FIG. 2, additional details of the reagent delivery system 101 of the hybrid nucleic acid analyzer system 100 are shown. The reagent delivery system 101 includes a syringe pump 200 that delivers a carrier 201 to a holding coil 202. The carrier is available to a zone fluidics system. The zone fluidics system provides sequential injection analysis (SIA).
  • Zone fluidics defines a general-purpose fluidics tool, allowing the precise manipulation of gases, liquids and solids to accomplish very complex analytical manipulations with relatively simple hardware. Zone fluidics is the precisely controlled physical, chemical, and fluid-dynamic manipulation of zones of miscible and immiscible fluids in narrow bore conduits to accomplish sample conditioning and chemical analysis. A zone is a volume region within a flow conduit containing at least one unique characteristic.
  • A unit operation in zone fluidics comprises of a set of fluid handling steps intended to contribute to the transformation of the sample into a detectable species or prepare it for manipulation in subsequent unit operations. Examples of unit operations include sample filtering, dilution, enrichment, medium exchange, headspace sampling, solvent extraction, matrix elimination, de-bubbling, amplifying, hybridizing, and reacting. In current analytical practice many of these steps are handled manually or in isolated pieces of equipment. Integration is scant at best, and there is a high degree of analyst involvement. In zone fluidics, sample and reagent zones are subjected to these unit operations in a sequential manner being transported from one unit operation to the next under fluidic control.
  • Zone fluidics provides an alternative approach whereby unit operations are performed in narrow bore conduits and the transportation medium, instead of being mechanical as in robotics, is fluidic. At the heart of a zone fluidics manifold is a multi-position selection valve. Fluids are propelled and manipulated in the manifold by means of a bi-directional flow pump. A holding coil between the pump and valve is used to stack zones and mix adjacent zones through dispersion and diffusion as is practiced in sequential injection analysis (SIA).
  • The ports of the multi-position valve are coupled to various reservoirs, reactors, manifold devices, and detectors as indicated. Narrow bore conduits comprise the flow channels and provide fluid contact between manifold devices and components. The term fluid refers to liquids, gases, aerosols, and suspensions. Samples in zone fluidics are not limited to liquids. Rather, gases, and suspensions containing solids or cells are also included. Where solid samples are used, particles are limited to a size that ensures no blockages.
  • In most cases, reagents are prepared and then coupled to the zone fluidics manifold. The metering capability of the pump and mixing unit operations allow for reagents and standards to be prepared in situ. Reagents can therefore be presented to the zone fluidics manifold in an appropriately designed cartridge as ready-made, reagent concentrates, lyophilized, or crystalline form. Standards can be plumbed to the multi-position valve as discrete reservoirs providing the required range of concentrations. As for reagents though, standards can also be prepared in situ or diluted to cover a larger dynamic range.
  • In the reagent delivery system 101, a syringe pump 200 delivers a carrier 201 to a holding coil 202. The carrier is available to a zone fluidics system. The zone fluidics system provides in sequential injection analysis (SIA). The ports of a multi-position valve 203 of the zone fluidics sequential injection analysis system are coupled to air reservoir 204, negative reservoir 205, field sample reservoir 206, reagent reservoir 207, plug 208, waste 209, bleach reservoir 210, and bleach reservoir 211 as indicated. The zone fluidics sequential injection analysis system has an outlet 212 that delivers PCR reagents to the thermal cycler 102.
  • Referring now to FIG. 3, details of the thermal cycler 102 of the hybrid nucleic acid analyzer system 100 of the present invention are shown. Currently available Polymerase Chain Reaction (PCR) thermal cycling units are large cumbersome and non-portable. Some examples of commercially available semi-portable instruments include the iCycler manufactured by Bio-Rad, the Light cycler from Idaho Technologies and the Smart Cycler from Cepheid Inc. Real-time PCR works by including in a reaction mix sequence specific oligonucleotides (primer) that can be extended at its 3′ end and a third non-extendable oligonucleotide (probe) that has two fluorescence molecules attached to its 5′ and 3′ end respectively. Thus the probe is quenched due to the Fluorescence Resonance Energy Transfer (FRET) between the two fluorescent molecules. FRET is dependent on the sixth power of the intermolecular separation of the two fluorophores. In the absence of primer extension, there is no fluorescence signal detected by the fluorimeter. The enzyme DNA polymerase has 5′-3′ exo-nuclease activity as well as 5′-3′ polymerase activity. During primer extension, the fluorophore is cleaved from the 5′ end of the probe and since the fluorophore is no longer quenched, a signal is detected by the fluorimeter. These instruments are designed for measuring the fluorescence released from sequence specific probes in case of a positive identification. At present the multiplexing of nucleic acid signatures is limited by the number of fluorophores that can be used in the commercial instruments, due to spectral overlap of most of these fluorophores.
  • The thermal cycler 102 of the present invention can be a unit such as that described in U.S. Pat. No. 5,589,136 issued Dec. 31, 1996 to M. Allen Northrup, Raymond P. Mariella, Jr., Anthony V. Carrano, and Joseph W. Balch and assigned to the Regents of the University of California or in U.S. Pat. No. 6,586,233 issued Jul. 1, 2003 to William J. Benett. James B. Richards, and Fred P. Milanovich and assigned to the Regents of the University of California. The disclosures of U.S. Pat. No. 5,589,136 issued Dec. 31, 1996 and U.S. Pat. No. 6,586,233 issued Jul. 1, 2003 are incorporated herein by this reference. As show in FIG. 3, a chamber unit 300 is fabricated of circuit board material. The system can be constructed of materials such as circuit board fiberglass, silicon, ceramics, metal, or glass. Advantages of using circuit board fiberglass is the fact that it is not as thermally conductive as the other materials and the heating is more efficiently applied to the sample rather than being conducted to surrounding materials. Circuit board material is readily available and the technology of producing and working with circuit board material is highly developed. Circuit board material provides lower cost techniques for fabrication. Printed circuit board technology incorporates photolithography, metal etching, numerically controlled machining, and layering technologies to produce the desired device.
  • As shown in FIG. 3, the thermal cycler 102 is generally indicated at 300. The thermal cycler 102 includes a silicon-based sleeve as a chemical reaction chamber, generally indicated at 301, constructed of two bonded silicon parts, and which utilizes doped polysilicon for heating and bulk silicon for convective cooling, as described in greater detail hereinafter. The sleeve 301 includes a slot or opening 304 into which reaction fluid, indicated at 306, from a conduit 305 is inserted into the reaction chamber. The conduit 305 is constructed of plastic, for example, or other material which is inert with respect to the reaction mixture, thereby alleviating any potential material incompatibility issues. The sleeve is also provided with an opening 302 in which is located an optical window 303, made, for example, of silicon nitride, silicon dioxide, or polymers. The silicon sleeve reaction chamber 301 includes doped polysilicon for heating and bulk silicon for convective cooling, and combines a critical ratio of silicon and silicon nitride to the volume of material to be heated (e.g., liquid) in order to provide uniform heating, yet low power requirements.
  • The thermal cycler 102 can be used to rapidly and repetitively provide controlled thermal cycles to the reaction mixture. The thermal conductivity properties of the silicon or similar semiconducting substrate, help speed up the thermal rise and fall times, and allow low power operation. While silicon is unique in its thermal properties, i.e., high thermal conductivity, a combination of silicon, silicon nitride, silicon dioxide, polymers and other materials would provide a combination of thermal conductivity and insulation that would allow thermal uniformity and low power operation.
  • The Sample and the nucleic acid reaction mix are introduced into the thermal cycler 102 by the Sequential Injection Analysis fluid handling system illustrated in FIG. 2. As the sample is continuously driven by convection through the channels it passes through sections of channel that are temperature controlled to be at the upper and lower temperatures required for the PCR reaction. This continuous flow through the PCR temperature zones effectively thermally cycles the sample.
  • Referring now to FIG. 4, additional details of the hybridization chamber 103 of the hybrid nucleic acid analyzer system 100 are shown. In the hybridization chamber 103 the amplified mix is hybridized to luminex beads in-line before being sent to the Flow Cytometer 104 for analysis. A multi-position valve 400 in the hybridization chamber 103 is coupled to air reservoir 401, reporter reservoir 402, hybridization thermocycler 403, archive reservoir 404, plug 405, waste 406, holding coil 407, beads 408, and bleach reservoir 409 as indicated. The hybridization chamber 103 uses a simple copper coil around the reaction chamber to heat the bead and PCR mixture to the denaturation temperature. After denaturation, the chamber is brought to its hybridization temperature of 55-60° C. with a fan placed at the bottom of the unit. The multi-position valve 400 delivers the beads and sample to the bead trap 410 and to a multi-position valve 411. The multi-position valve 411 is coupled to air reservoir 412, plug 413, Cal beads 414, and waste 415 as indicated. The hybridization chamber 103 has an outlet 416 that delivers the hybridized sample to the flow cytometer 104.
  • Referring now to FIG. 5, schematics of the hybridization chamber 103 of the hybrid nucleic acid Analyzer are shown. A copper tube support 500 provides a support for the hybridization chamber 103 and its associated equipment. As shown in FIG. 5, the hybridization chamber 103 includes a temperature control sensor 501, heatshrink insulation 502, a muffin fan 503, a foil heater 504, tubing 505, and a fan 506. The heater 504 heats the chamber to the denaturation temperature of 95° C. followed by a cooling to the required hybridization temperature with the aid of the fans 503 and 506. The PID temperature control sensor 501 precisely monitors the denaturation and hybridization temperatures within a couple of degrees. The hybridization chamber 103 provides a single step movement of hybridization reagents into the chamber.
  • In the hybridization chamber 103 the amplified mix is hybridized to luminex beads in-line before being sent to the Flow Cytometer 104 for analysis. The hybridization chamber 103 heats the bead and PCR mixture to the denaturation chamber. After denaturation, the chamber is brought to its hybridization temperature of 55-60° C. with the fans 503 and 506. The hybridization chamber 103 has an outlet that delivers the hybridized sample to the flow cytometer 104.
  • Referring now to FIG. 6, additional details of the flow cytometer 104 of the hybrid nucleic acid analyzer system 100 are shown. The flow cytometer 104 comprises a Luminex LX100 Flow Cytometer instrument 600 with a sheath source 601 and a waste reservoir 602. The hybridized bead array is from the hybridization camber 103 is introduced into the Luminex Flow Cytometer instrument 600 where the beads are interrogated by two lasers, a red laser for the internal discriminator and a green laser for the external discriminator dyes respectively. Additional details of the flow cytometer 600 and its operation are show in FIGS. 7, 8, 9, and 10.
  • The protein (toxin or antigen) assay on the liquid bead arrays is a typical sandwich assay. The antibody specific to the antigen or a toxin is attached to the surface of Carboxylated polystyrene beads described above. The antigen is then hybridized to the bead sets followed by a secondary antibody to which is attached the secondary discriminator phycoerythrin.
  • In order to multiplex more than four signatures, Applicants have designed a Luminex Bead based Array analyzer. With the liquid arrays it is possible to multiplex over 100 different organisms. The discrimination of the polystyrene Luminex bead array is dependent on the precise ratio of two internal discriminator dyes, a red and an infrared dye. The signal intensity on the surface of the bead is dependent on the concentration of the analyte in solution, in our case the amplified DNA of a suspect agent or an antigen or a toxin, whichever the case may be.
  • Referring now to FIG. 7, the beads used in the hybridization chamber 103 and the flow cytometer 104 are illustrated. A 100-plex Luminex liquid array 700 is generated by intercalating varying ratios of red and orange infrared dyes into polystyrene latex microspheres or beads 701. The process of producing varying ratios of red and orange infrared dyes in the beads 701 is accomplished by increasing the amount of red dye as illustrated by the arrow 702 and increasing the amount of orange dye as illustrated by the arrow 703. This gives each optically encoded bead 700 a unique spectral address.
  • Referring now to FIG. 8, additional information is provided illustrating how the beads are used in the hybridization chamber 103 and the flow cytometer 104. The beads designated by the reference numeral 800 are coated with capture antibodies specific for target antigens. Each bead has an attachment site specific for a bioagent. The upper bead has an attachment site 801 for anthrax. The next bead has an attachment site 802 for plague. The next bead has an attachment site 803 for small pox. The next bead has an attachment site 804 for botox. The attachment site 801 for anthrax attaches to the anthrax bioagent 805. The attachment site 802 for plague attaches to the plague bioagent 806. The attachment site 803 for small pox attaches to the small pox bioagent 807. The attachment site 804 for botox attaches to the botox bioagent 808. After incubation with the antigens, secondary or detector antibodies are added, followed by addition of the fluorescent reporter, phycoerythrin 809 to complete the “antigen sandwich.”
  • Referring now to FIG. 9, additional information is provided illustrating how the beads are used in the hybridization chamber 103 and in the flow cytometer 104. The beads are designated by the reference numeral 900. FIG. 9 illustrates bead hybridization with amplified PCR product. The PCR product 901 is added to labeled luminex bead mix and denatured. This is followed by hybridization and addition of SA-PE 902. The hybridized beads are then detected in the Luminex flow cytometer 104.
  • Referring now to FIG. 10, an illustration shows how the beads are analyzed in the flow cytometer. The beads are designated by the reference numeral 1000. The direction of flow is shown by the arrow 1001. The beads 1000 are interrogated one at a time. As illustrated, one bead 1000 is shown being interrogated. A red laser classifies the bead 1000, identifying the bead type. Subsequently a green laser 1002 quantifies the assay on the bead surface—only those beads with a complete sandwich will produce a fluoresce 1003 in the green, and the signal is a function of antigen concentration.
  • The structural details of various embodiments of a hybrid nucleic acid analyzer constructed in accordance with the present invention having been illustrated in FIGS. 1-10 and described above, the operation of the hybrid nucleic acid analyzer will now be considered. The hybrid nucleic acid analyzer provides an integrated nucleic acid and protein/toxin detection system capable of in-line analysis of a complex sample within an hour or less. The rate limiting step is the rapidity with which the nucleic acid is amplified, the hybridization being instantaneous. The hybrid nucleic acid analyzer has the capability of performing continuous nucleic acid and immunoassays in a multiplex format. The hybrid nucleic acid analyzer is a field deployable instrument for detection of pathogens and toxins in environmental or clinical samples. The hybrid nucleic acid analyzer takes advantage of the multiplexing capability of the Luminex Bead arrays complexed with multiplexed nucleic acid and protein capability developed at the Lawrence Livermore National Laboratory.
  • The hybrid nucleic acid analyzer has an integrated PCR chamber 102, DNA Hybridization chamber 103, and Luminex LX100 flow cytometer 104 controlled by a LabView interface software for the fluidic handling and the operation of the PCR chamber. The software is integrated into a form compatible with the Graphical User Interface (GUI) used to control and monitor the Luminex LX100 flow cytometer. Control and data analysis software routines have been written for controlling the Luminex LX100 flow cytometry. Provisions have been made for the addition of a sample preparation and concentration unit as well as a bead sequestering unit in order to facilitate deep multiplexing of the agents. A sample preparation and concentration strategy involves the use of Silicon pillar chips capable of handling volumes of up to 100 ml or more of the sample, releasing the DNA from the cells through lysis and concentrating it in a small volume for analysis, thus increasing the detection limit many folds.
  • The fluidics in the instrument is self-contained in order to minimize contamination of the surroundings and the operator. This minimizes contamination of reagents and samples, a feature not available in commercial units. The sample and the nucleic acid reaction mix are introduced into the thermal cycler 102 by Sequential Injection Analysis fluid handling system 101.
  • The hybridization chamber 103 uses a simple copper coil around the reaction chamber to heat the bead and PCR mixture to the denaturation chamber. After denaturation, the chamber is brought to its hybridization temperature of 55-60° C. with a fan placed at the bottom of the unit. A thermocouple inserted in the housing of the hybridization chamber as well as on the silicon sleeve of the thermal cycling chamber is used to control the temperatures via feed back from a PID controller. In this instrument the reagents are pre-loaded onto the system so that there is minimal user interface.
  • Once the sample is introduced into the instrument 100, the detection is autonomously done following the sequence of events input by the researcher. Decontamination of the fluidics system is carried out autonomously after each amplification step. The system including the PCR chamber 102, the hybridization chamber 103, the tubing carrying the sample to the PCR chamber and all the tubing and fitting downstream from there on are rinsed with 5% household bleach which we have found sufficient to effectively remove all traces of nucleic acids or PCR product from the housing. After every PCR run, a negative control for the agent/agents is amplified in order to determine the efficacy of the decontamination process.
  • Manual labor is the major factor for the high cost of sample testing. The software has the capability of stacking a series of fluidic protocols for autonomous analysis. Thus the instrument 100 can be loaded with the reagents and the samples at the beginning of the day and the results can be accessed from a remote location. This cuts the cost of labor as compared to the conventional way of doing analysis. Thus with this instrument it is possible to perform continuous analysis of samples from a known set of reagents with minimal intervention in effect significantly reducing the cost of the assay.
  • The hybrid nucleic acid analyzer 100 provides autonomous use of both the thermal cycler 102 and the flow cytometer 104 such that protein analysis can be performed independent of the nucleic acid detection. For detection of antigens or toxins, the sample is introduced directly to appropriately labeled beads followed by hybridization to the secondary antibody and analysis of the assay in the flow cytometer 104. The hybrid nucleic acid analyzer 100 can be repeatedly decontaminated in between runs with a solution of 5% household bleach.
  • The nucleic acid detection is done by hybridization of the amplified PCR product with the probes attached to the surface of the bead sets via NHS ester linkage chemistry. The PCR product is labeled with Biotin molecules and the hybridization of the product to the beads is followed by streptavidin phycoerythrin addition to the hybridized reaction mix.
  • The hybrid nucleic acid analyzer system 100 provides a closed integrated rapid Real-time PCR and multiplex flow analysis instrument for identification of multiplex pathogen and toxin within an hour with minimal exposure to the technician. The hybrid nucleic acid analyzer system 100 combines Real-time flow through PCR with an inline flow cytometer to detect both nucleic acids as well as proteins. Sequential injection analysis (SIA) fluidic system is used to deliver the sample and reagent for in-line mixing, analysis and archiving of samples.
  • The unused PCR reaction mix is moved to the waste stream. The hybrid system is decontaminated and made ready for another round of amplification by rinsing with a 5% solution of Household Bleach followed by water rinse. A negative reaction with water substituted for sample is run between sample amplifications to ensure that the system is free of carry over PCR product.
  • The hybrid nucleic acid analyzer 100 has many uses. For example, the system 100 has use for clinical analysis of blood bank samples in a continuous 24/7 analysis of pathogens. The system 100 has use in diagnostic labs. The system 100 has use as a fly away lab or integrated into continuous monitoring of environmental samples for detection of Biothreat agents. The system 100 also has use in automated processing, amplification and detection of biological molecules in forensic samples. The system 100 can also be used for automated clinical testing, analysis and archiving in event of an outbreak. The system 100 can also be used to detect proteins and toxins both in the clinic as well as from the environment.
  • While the invention may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the following appended claims.

Claims (54)

1. A nucleic acid assay apparatus for analyzing a sample using a reagent, comprising:
a thermal cycler,
a sample and reagent delivery unit operatively connected to said thermal cycler for delivering the sample and the reagent to said thermal cycler,
a hybridization chamber operatively connected to said thermal cycler, and
a flow cytometer operatively connected to said hybridization chamber.
2. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize beads with each bead having a unique spectral address.
3. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize polystyrene latex microspheres beads with each bead having a unique spectral address.
4. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize beads with varying ratios of red and orange infrared dyes giving each bead a unique spectral address.
5. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize a 100-plex array of beads with varying ratios of red and orange infrared dyes giving each bead a unique spectral address.
6. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize beads with each bead having a capture antibody specific for a target antigen.
7. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize beads with at least one bead having an anthrax capture antibody specific for a target anthrax antigen.
8. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize beads with at least one bead having a plague capture antibody specific for a target plague antigen.
9. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize beads with at least one bead having a small pox capture antibody specific for a target small pox antigen.
10. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize beads with at least one bead having a botox capture antibody specific for a target botox antigen.
11. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize beads with each bead having a capture antibody specific for a target antigen and a fluorescent reporter.
12. The nucleic acid assay apparatus of claim 1 wherein said flow cytometer utilizes at least one laser.
13. The nucleic acid assay apparatus of claim 1 wherein said flow cytometer utilizes a red laser.
14. The nucleic acid assay apparatus of claim 1 wherein said flow cytometer utilizes a green laser.
15. The nucleic acid assay apparatus of claim 1 wherein said flow cytometer utilizes a red laser and a green laser.
16. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize beads with each bead having a fluorescent reporter and said flow cytometer utilizes at least one laser for bead interrogation by fluoresce of said fluorescent reporter.
17. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize beads with each bead having a capture antibody specific for a target antigen and a fluorescent reporter and said flow cytometer utilizes at least one laser for bead interrogation.
18. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber and said flow cytometer utilize beads with each bead having a capture antibody specific for a target antigen and a fluorescent reporter and said flow cytometer utilizes a green laser for bead interrogation by fluoresce of said fluorescent reporter.
19. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber includes a heater.
20. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber includes a fan.
21. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber includes a heater and a fan.
22. The nucleic acid assay apparatus of claim 1 wherein said hybridization chamber includes a heater, a fan, and a temperature control sensor.
23. A nucleic acid assay apparatus for analyzing a sample using a reagent, comprising:
thermal cycler means,
sample and reagent delivery means operatively connected to said thermal cycler means for delivering the sample and the reagent to said thermal cycler means,
hybridization means operatively connected to said thermal cycler means, and
flow cytometer means operatively connected to said hybridization means.
24. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize beads with each bead having a unique spectral address.
25. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize polystyrene latex microspheres beads with each bead having a unique spectral address.
26. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize beads with varying ratios of red and orange infrared dyes giving each bead a unique spectral address.
27. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize a 100-plex array of beads with varying ratios of red and orange infrared dyes giving each bead a unique spectral address.
28. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize beads with each bead having a capture antibody specific for a target antigen.
29. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize beads with at least one bead having an anthrax capture antibody specific for a target anthrax antigen.
30. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize beads with at least one bead having a plague capture antibody specific for a target plague antigen.
31. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize beads with at least one bead having a small pox capture antibody specific for a target small pox antigen.
32. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize beads with at least one bead having a botox capture antibody specific for a target botox antigen.
33. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize beads with each bead having a capture antibody specific for a target antigen and a fluorescent reporter.
34. The nucleic acid assay apparatus of claim 23 wherein said flow cytometer means utilizes at least one laser.
35. The nucleic acid assay apparatus of claim 23 wherein said flow cytometer means utilizes a red laser.
36. The nucleic acid assay apparatus of claim 23 wherein said flow cytometer means utilizes a green laser.
37. The nucleic acid assay apparatus of claim 23 wherein said flow cytometer means utilizes a red laser and a green laser.
38. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize beads with each bead having a fluorescent reporter and said flow cytometer means utilizes at least one laser for bead interrogation by fluoresce of said fluorescent reporter.
39. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize beads with each bead having a capture antibody specific for a target antigen and a fluorescent reporter and said flow cytometer means utilizes at least one laser for bead interrogation.
40. The nucleic acid assay apparatus of claim 23 wherein said hybridization means and said flow cytometer means utilize beads with each bead having a capture antibody specific for a target antigen and a fluorescent reporter and said flow cytometer means utilizes a green laser for bead interrogation by fluoresce of said fluorescent reporter.
41. The nucleic acid assay apparatus of claim 23 wherein said hybridization means includes a heater.
42. The nucleic acid assay apparatus of claim 23 wherein said hybridization means includes a fan.
43. The nucleic acid assay apparatus of claim 23 wherein said hybridization means includes a heater and a fan.
44. The nucleic acid assay apparatus of claim 23 wherein said hybridization means includes a heater, a fan, and a temperature control sensor.
45. A nucleic acid assay method for analyzing a sample using a reagent, comprising the steps of:
providing a thermal cycler,
providing a hybridization unit,
providing a flow cytometer,
transporting the sample and the reagent to said thermal cycler for amplification, and
analyzing the sample with said flow cytometer utilize beads with each bead having a unique spectral address.
46. The nucleic acid assay method of claim 45 wherein said step of analyzing the sample with said flow cytometer comprises utilizing polystyrene latex microspheres beads with each bead having a unique spectral address.
47. The nucleic acid assay method of claim 45 wherein said step of analyzing the sample with said flow cytometer comprises utilizing beads with varying ratios of red and orange infrared dyes giving each bead a unique spectral address.
48. The nucleic acid assay method of claim 45 wherein said step of analyzing the sample with said flow cytometer comprises utilizing a 100-plex array of beads with varying ratios of red and orange infrared dyes giving each bead a unique spectral address.
49. The nucleic acid assay method of claim 45 wherein said step of analyzing the sample with said flow cytometer comprises utilizing beads with each bead having a capture antibody specific for a target antigen.
50. The nucleic acid assay method of claim 45 wherein said step of analyzing the sample with said flow cytometer comprises utilizing beads with at least one bead having an anthrax capture antibody specific for a target anthrax antigen.
51. The nucleic acid assay method of claim 45 wherein said step of analyzing the sample with said flow cytometer comprises utilizing beads with at least one bead having a plague capture antibody specific for a target plague antigen.
52. The nucleic acid assay method of claim 45 wherein said step of analyzing the sample with said flow cytometer comprises utilizing beads with at least one bead having a small pox capture antibody specific for a target small pox antigen.
53. The nucleic acid assay method of claim 45 wherein said step of analyzing the sample with said flow cytometer comprises utilizing beads with at least one bead having a botox capture antibody specific for a target botox antigen.
54. The nucleic acid assay method of claim 45 wherein said step of analyzing the sample with said flow cytometer comprises utilizing beads with each bead having a capture antibody specific for a target antigen and a fluorescent reporter.
US11/159,008 2002-08-26 2005-06-21 Hybrid automated continuous nucleic acid and protein analyzer using real-time PCR and liquid bead arrays Abandoned US20050239192A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/159,008 US20050239192A1 (en) 2002-08-26 2005-06-21 Hybrid automated continuous nucleic acid and protein analyzer using real-time PCR and liquid bead arrays

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40615902P 2002-08-26 2002-08-26
US10/643,797 US20040038385A1 (en) 2002-08-26 2003-08-19 System for autonomous monitoring of bioagents
US11/159,008 US20050239192A1 (en) 2002-08-26 2005-06-21 Hybrid automated continuous nucleic acid and protein analyzer using real-time PCR and liquid bead arrays

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/643,797 Continuation-In-Part US20040038385A1 (en) 2002-08-26 2003-08-19 System for autonomous monitoring of bioagents

Publications (1)

Publication Number Publication Date
US20050239192A1 true US20050239192A1 (en) 2005-10-27

Family

ID=31891539

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/643,797 Abandoned US20040038385A1 (en) 2002-08-26 2003-08-19 System for autonomous monitoring of bioagents
US11/000,491 Abandoned US20060057599A1 (en) 2002-08-26 2004-11-29 System for autonomous monitoring of bioagents
US11/159,008 Abandoned US20050239192A1 (en) 2002-08-26 2005-06-21 Hybrid automated continuous nucleic acid and protein analyzer using real-time PCR and liquid bead arrays
US12/786,248 Expired - Fee Related US9052255B2 (en) 2002-08-26 2010-05-24 System for autonomous monitoring of bioagents

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/643,797 Abandoned US20040038385A1 (en) 2002-08-26 2003-08-19 System for autonomous monitoring of bioagents
US11/000,491 Abandoned US20060057599A1 (en) 2002-08-26 2004-11-29 System for autonomous monitoring of bioagents

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/786,248 Expired - Fee Related US9052255B2 (en) 2002-08-26 2010-05-24 System for autonomous monitoring of bioagents

Country Status (6)

Country Link
US (4) US20040038385A1 (en)
EP (1) EP1576353A2 (en)
JP (1) JP2006508371A (en)
AU (1) AU2003304254B2 (en)
CA (1) CA2496128A1 (en)
WO (1) WO2005001435A2 (en)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292889A1 (en) * 2006-06-16 2007-12-20 The Regents Of The University Of California Immunoassay magnetic trapping device
US20080048874A1 (en) * 2006-08-24 2008-02-28 Microfluidic Systems, Inc. Integrated airborne substance collection and detection system
US20080166793A1 (en) * 2007-01-04 2008-07-10 The Regents Of The University Of California Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture
US20080183433A1 (en) * 2007-01-30 2008-07-31 The Regents Of The University Of California Detection and quantification system for monitoring instruments
US20080253294A1 (en) * 2001-12-14 2008-10-16 Alberto Alessandro Della Ripa Data link fault tolerance
WO2009111072A1 (en) * 2008-03-05 2009-09-11 Clean Earth Technologies, Llc Multiplexed pcr-coupled pna labeled beads flow cytometric assay for simultaneous detection of multiple biological agents
WO2010009426A2 (en) * 2008-07-17 2010-01-21 Life Technologies Corporation Devices and methods for reagent delivery
US20100050742A1 (en) * 2006-08-24 2010-03-04 Microfluidic Systems, Inc. Integrated airborne substance collection and detection system
US20100050749A1 (en) * 2008-08-28 2010-03-04 MicroFluidic Systems, Ltd. Sample preparation apparatus
USRE41780E1 (en) 2003-03-14 2010-09-28 Lawrence Livermore National Security, Llc Chemical amplification based on fluid partitioning in an immiscible liquid
US7858366B2 (en) 2006-08-24 2010-12-28 Microfluidic Systems, Inc Integrated airborne substance collection and detection system
US7889729B2 (en) 2001-12-20 2011-02-15 Qualcomm Incorporated System and method for reevaluating granted arbitrated bids
US8418129B1 (en) 2001-12-14 2013-04-09 Qualcomm Incorporated Method for automatically generating code to define a system of hardware elements
US8633015B2 (en) 2008-09-23 2014-01-21 Bio-Rad Laboratories, Inc. Flow-based thermocycling system with thermoelectric cooler
US8663920B2 (en) 2011-07-29 2014-03-04 Bio-Rad Laboratories, Inc. Library characterization by digital assay
WO2014058486A1 (en) 2012-06-25 2014-04-17 Diagnostic Consulting Network, Inc. Kits and methods for cyanide detection
US8709762B2 (en) 2010-03-02 2014-04-29 Bio-Rad Laboratories, Inc. System for hot-start amplification via a multiple emulsion
US8730479B2 (en) 2010-03-25 2014-05-20 Bio-Rad Laboratories, Inc. Detection system for droplet-based assays
US8951939B2 (en) 2011-07-12 2015-02-10 Bio-Rad Laboratories, Inc. Digital assays with multiplexed detection of two or more targets in the same optical channel
US9089844B2 (en) 2010-11-01 2015-07-28 Bio-Rad Laboratories, Inc. System for forming emulsions
US9126160B2 (en) 2008-09-23 2015-09-08 Bio-Rad Laboratories, Inc. System for forming an array of emulsions
US9132394B2 (en) 2008-09-23 2015-09-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US9194861B2 (en) 2009-09-02 2015-11-24 Bio-Rad Laboratories, Inc. Method of mixing fluids by coalescence of multiple emulsions
US9222128B2 (en) 2011-03-18 2015-12-29 Bio-Rad Laboratories, Inc. Multiplexed digital assays with combinatorial use of signals
US9347059B2 (en) 2011-04-25 2016-05-24 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US9393560B2 (en) 2010-03-25 2016-07-19 Bio-Rad Laboratories, Inc. Droplet transport system for detection
US9399215B2 (en) 2012-04-13 2016-07-26 Bio-Rad Laboratories, Inc. Sample holder with a well having a wicking promoter
US9417190B2 (en) 2008-09-23 2016-08-16 Bio-Rad Laboratories, Inc. Calibrations and controls for droplet-based assays
US9492797B2 (en) 2008-09-23 2016-11-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US9500664B2 (en) 2010-03-25 2016-11-22 Bio-Rad Laboratories, Inc. Droplet generation for droplet-based assays
US9598725B2 (en) 2010-03-02 2017-03-21 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US9764322B2 (en) 2008-09-23 2017-09-19 Bio-Rad Laboratories, Inc. System for generating droplets with pressure monitoring
US10472669B2 (en) 2010-04-05 2019-11-12 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10512910B2 (en) 2008-09-23 2019-12-24 Bio-Rad Laboratories, Inc. Droplet-based analysis method
US10774372B2 (en) 2013-06-25 2020-09-15 Prognosy s Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US10774374B2 (en) 2015-04-10 2020-09-15 Spatial Transcriptomics AB and Illumina, Inc. Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11130128B2 (en) 2008-09-23 2021-09-28 Bio-Rad Laboratories, Inc. Detection method for a target nucleic acid
US11352659B2 (en) 2011-04-13 2022-06-07 Spatial Transcriptomics Ab Methods of detecting analytes
US11624086B2 (en) 2020-05-22 2023-04-11 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11733238B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009120183A2 (en) * 2007-12-20 2009-10-01 Biotrove, Inc. System for the detection of a biological pathogen and use thereof
CA2290731A1 (en) * 1999-11-26 2001-05-26 D. Jed Harrison Apparatus and method for trapping bead based reagents within microfluidic analysis system
US6432290B1 (en) 1999-11-26 2002-08-13 The Governors Of The University Of Alberta Apparatus and method for trapping bead based reagents within microfluidic analysis systems
US20030027135A1 (en) * 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
US20040121313A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in organs for transplantation
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US7718354B2 (en) 2001-03-02 2010-05-18 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US20070166725A1 (en) * 2006-01-18 2007-07-19 The Regents Of The University Of California Multiplexed diagnostic platform for point-of care pathogen detection
US20040038385A1 (en) * 2002-08-26 2004-02-26 Langlois Richard G. System for autonomous monitoring of bioagents
EP1578399A4 (en) 2002-12-06 2007-11-28 Isis Pharmaceuticals Inc Methods for rapid identification of pathogens in humans and animals
AU2003303594A1 (en) * 2002-12-30 2004-07-29 The Regents Of The University Of California Methods and apparatus for pathogen detection and analysis
WO2004083806A2 (en) * 2003-01-22 2004-09-30 University Of South Florida Autonomous genosensor apparatus and methods for use
US8046171B2 (en) * 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US7964343B2 (en) * 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8158354B2 (en) * 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US20080138808A1 (en) * 2003-09-11 2008-06-12 Hall Thomas A Methods for identification of sepsis-causing bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US20100035239A1 (en) * 2003-09-11 2010-02-11 Isis Pharmaceuticals, Inc. Compositions for use in identification of bacteria
US20120122103A1 (en) * 2003-09-11 2012-05-17 Rangarajan Sampath Compositions for use in identification of bacteria
US20060240412A1 (en) * 2003-09-11 2006-10-26 Hall Thomas A Compositions for use in identification of adenoviruses
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
WO2005078674A2 (en) * 2003-12-10 2005-08-25 Smiths Detection Inc. Autonomous surveillance system
WO2005079340A2 (en) * 2004-02-13 2005-09-01 Lacasse Photoplastics, Inc. Intelligent directional fire alarm system
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en) * 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
ES2641832T3 (en) 2004-05-24 2017-11-14 Ibis Biosciences, Inc. Mass spectrometry with selective ion filtration by setting digital thresholds
US20050266411A1 (en) * 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
US7799553B2 (en) 2004-06-01 2010-09-21 The Regents Of The University Of California Microfabricated integrated DNA analysis system
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
CN101073002B (en) 2004-09-15 2012-08-08 英特基因有限公司 Microfluidic devices
WO2007064313A2 (en) * 2004-11-24 2007-06-07 Invitrogen Corporation Biological confirmation and detection system
JP4765059B2 (en) * 2005-02-10 2011-09-07 国立大学法人北海道大学 Cognitive task response measurement system and cognitive task response measurement method
US20060281101A1 (en) * 2005-02-17 2006-12-14 The Regents Of The University Of California Biobriefcase
US8084207B2 (en) * 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
WO2006094238A2 (en) 2005-03-03 2006-09-08 Isis Pharmaceuticals, Inc. Compositions for use in identification of adventitious viruses
US20070026426A1 (en) 2005-04-26 2007-02-01 Applera Corporation System for genetic surveillance and analysis
AU2006272776B2 (en) * 2005-07-21 2012-01-19 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
US20070053188A1 (en) * 2005-09-06 2007-03-08 Luminator Holding, L.P. LED ultraviolet air sanitizer light fixture
US7503230B2 (en) * 2005-11-08 2009-03-17 Lawrence Livermore National Security, Llc Biobriefcase aerosol collector heater
WO2008030631A2 (en) * 2006-02-03 2008-03-13 Microchip Biotechnologies, Inc. Microfluidic devices
US7766033B2 (en) 2006-03-22 2010-08-03 The Regents Of The University Of California Multiplexed latching valves for microfluidic devices and processors
WO2008054480A2 (en) * 2006-03-22 2008-05-08 Northrop Grumman Corporation Enhanced biohazard detection system
DE102006025200A1 (en) * 2006-05-29 2007-12-06 Francotyp-Postalia Gmbh Closing fluid for security closures
US9383322B2 (en) 2006-05-29 2016-07-05 Fracotyp-Postalia GmbH Kit containing sealing liquid for safety closures
EP2064332B1 (en) * 2006-09-14 2012-07-18 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US8841116B2 (en) 2006-10-25 2014-09-23 The Regents Of The University Of California Inline-injection microdevice and microfabricated integrated DNA analysis system using same
US20080168752A1 (en) * 2006-12-22 2008-07-17 Perma Pure, Llc Separating particulate-containing gas flow into particulate and non-particulate flow portions
EP2109666A4 (en) 2007-02-05 2011-09-14 Integenx Inc Microfluidic and nanofluidic devices, systems, and applications
WO2008104002A2 (en) * 2007-02-23 2008-08-28 Ibis Biosciences, Inc. Methods for rapid forensic dna analysis
US8298763B2 (en) * 2007-03-02 2012-10-30 Lawrence Livermore National Security, Llc Automated high-throughput flow-through real-time diagnostic system
WO2008118809A1 (en) * 2007-03-23 2008-10-02 Ibis Biosciences, Inc. Compositions for use in identification of mixed populations of bioagents
WO2008151023A2 (en) 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
FR2917095B1 (en) * 2007-06-07 2009-07-17 Biomerieux Sa DEVICE FOR LYING MICROORGANISMS PRESENT IN AN ENVIRONMENTAL OR CLINICAL SAMPLE AND EXTRACTING NUCLEIC ACIDS FROM SAID MICROORGANISMS FOR ANALYSIS.
US8454906B2 (en) * 2007-07-24 2013-06-04 The Regents Of The University Of California Microfabricated droplet generator for single molecule/cell genetic analysis in engineered monodispersed emulsions
US20090126514A1 (en) * 2007-09-05 2009-05-21 Eric Gregory Burroughs Devices for collection and preparation of biological agents
NZ584963A (en) 2007-10-02 2012-11-30 Theranos Inc Modular Point-of-care devices as addressible assay units with tips of assay units having interior to immobilize reagents by capillary action
EP2056114A1 (en) * 2007-10-29 2009-05-06 Koninklijke Philips Electronics N.V. Automatic detection of infectious diseases
US20090253181A1 (en) * 2008-01-22 2009-10-08 Microchip Biotechnologies, Inc. Universal sample preparation system and use in an integrated analysis system
US7867713B2 (en) * 2008-04-21 2011-01-11 Lawrence Livermore National Security, Llc Polymerase chain reaction system using magnetic beads for analyzing a sample that includes nucleic acid
US20110263044A1 (en) * 2008-07-31 2011-10-27 Eads Deutschland Gmbh Device and method for the automatic detection of biological particles
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
WO2010033599A2 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
EP2347254A2 (en) 2008-09-16 2011-07-27 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
FR2939445B1 (en) 2008-12-10 2013-05-03 Biomerieux Sa AUTOMATED LYSE SYSTEM OF MICROORGANISMS PRESENT IN SAMPLE, NUCLEIC ACID EXTRACTION AND PURIFICATION OF MICROORGANISMS FOR ANALYSIS
CN102341691A (en) * 2008-12-31 2012-02-01 尹特根埃克斯有限公司 Instrument with microfluidic chip
WO2010093943A1 (en) * 2009-02-12 2010-08-19 Ibis Biosciences, Inc. Ionization probe assemblies
JP4870243B2 (en) * 2009-04-01 2012-02-08 新日本製鐵株式会社 Apparatus and method for continuous measurement of dust horizontal flux in the atmosphere
WO2010113521A1 (en) * 2009-04-01 2010-10-07 新日本製鐵株式会社 Horizontal component catcher of dustfall in atmosphere and measuring method of horizontal component
US8388908B2 (en) * 2009-06-02 2013-03-05 Integenx Inc. Fluidic devices with diaphragm valves
CA2764464A1 (en) * 2009-06-05 2010-12-09 Integenx Inc. Universal sample preparation system and use in an integrated analysis system
US9194877B2 (en) 2009-07-17 2015-11-24 Ibis Biosciences, Inc. Systems for bioagent indentification
WO2011008971A1 (en) * 2009-07-17 2011-01-20 Ibis Biosciences, Inc. Lift and mount apparatus
US20110091882A1 (en) * 2009-10-02 2011-04-21 Ibis Biosciences, Inc. Determination of methylation status of polynucleotides
US8717164B2 (en) * 2009-10-09 2014-05-06 Wind Willie, Llc Integrated security system for warning of dangerous substances that are dispersed by winds
US9890408B2 (en) * 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
US8584703B2 (en) 2009-12-01 2013-11-19 Integenx Inc. Device with diaphragm valve
FR2957150A1 (en) * 2010-03-05 2011-09-09 Nosoco Tech METHOD AND APPARATUS FOR DETECTION IN CONTINUOUS AND IN REALLY REAL TIME OF TRACES OF MICROBES (BACTERIA, VIRUSES) OR DANGEROUS OR ILLEGAL SUBSTANCES (EXPLOSIVES, DRUGS) IN AN ATMOSPHERE
US8512538B2 (en) 2010-05-28 2013-08-20 Integenx Inc. Capillary electrophoresis device
EP2606154B1 (en) 2010-08-20 2019-09-25 Integenx Inc. Integrated analysis system
US8763642B2 (en) 2010-08-20 2014-07-01 Integenx Inc. Microfluidic devices with mechanically-sealed diaphragm valves
EP2666008B1 (en) 2011-01-21 2021-08-11 Labrador Diagnostics LLC Systems and methods for sample use maximization
NL2006600C2 (en) * 2011-02-11 2012-08-14 Dutch Water Technologies B V DEVICE AND METHOD FOR DETECTING TRACKS
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US8435738B2 (en) * 2011-09-25 2013-05-07 Theranos, Inc. Systems and methods for multi-analysis
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US8380541B1 (en) 2011-09-25 2013-02-19 Theranos, Inc. Systems and methods for collecting and transmitting assay results
DE102011053758A1 (en) * 2011-09-19 2013-03-21 BMA-Labor Gbr Method of analyzing air for the presence of biological substances
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US10865440B2 (en) 2011-10-21 2020-12-15 IntegenX, Inc. Sample preparation, processing and analysis systems
US20150136604A1 (en) 2011-10-21 2015-05-21 Integenx Inc. Sample preparation, processing and analysis systems
US8994556B2 (en) 2012-05-24 2015-03-31 Douglas H. Lundy Threat detection system and method
JP6075979B2 (en) * 2012-06-27 2017-02-08 リオン株式会社 Particle counting system
US10519434B2 (en) 2012-07-13 2019-12-31 Diomics Corporation Biologic sample collection devices and methods of production and use thereof
US20140046722A1 (en) * 2012-08-10 2014-02-13 Sample6 Technologies, Inc. System for on-site environment monitoring
JP6033643B2 (en) * 2012-11-07 2016-11-30 アズビル株式会社 Variable channel width virtual impactor
US10401373B1 (en) 2013-02-18 2019-09-03 Theranos Ip Company, Llc Systems and methods for analyte testing and laboratory oversight
AU2014217893A1 (en) * 2013-02-18 2015-07-30 Theranos Ip Company, Llc Systems and methods for multi-analysis
SG11201506421PA (en) 2013-02-18 2015-09-29 Theranos Inc Systems and methods for collecting and transmitting assay results
US11008628B1 (en) 2013-02-18 2021-05-18 Labrador Diagnostics Llc Systems and methods for analyte testing and laboratory oversight
US9169521B1 (en) * 2013-03-14 2015-10-27 The Boeing Company Point-of-collection sample preparation device and method
US10422806B1 (en) 2013-07-25 2019-09-24 Theranos Ip Company, Llc Methods for improving assays of biological samples
WO2015073999A1 (en) 2013-11-18 2015-05-21 Integenx Inc. Cartridges and instruments for sample analysis
US11360107B1 (en) 2014-02-25 2022-06-14 Labrador Diagnostics Llc Systems and methods for sample handling
US9454921B2 (en) 2014-03-24 2016-09-27 Wind Willie, Llc Integrated security system for warning of dangerous substances that are dispersed by winds
DE102014105437A1 (en) * 2014-04-16 2015-10-22 Amodia Bioservice Gmbh Microfluidic module and cassette for immunological and molecular diagnostics in an automated analyzer
WO2015179098A1 (en) 2014-05-21 2015-11-26 Integenx Inc. Fluidic cartridge with valve mechanism
JP6328493B2 (en) * 2014-05-28 2018-05-23 東京エレクトロン株式会社 Measuring apparatus and measuring method
US20160025603A1 (en) 2014-07-22 2016-01-28 Diomics Corporation Airborne agent collectors, methods, systems and devices for monitoring airborne agents
WO2016025021A1 (en) 2014-08-15 2016-02-18 Diomics Corporation Films for biologic analyte collection and analysis and methods of production and use thereof
CN107106983B (en) 2014-10-22 2021-04-16 尹特根埃克斯有限公司 Systems and methods for sample preparation, processing, and analysis
HUP1500115A2 (en) * 2015-03-17 2018-02-28 Brg Radiotechnikai Gepgyar Kft Device and method for collecting samples
JP6352894B2 (en) * 2015-12-24 2018-07-04 トヨタ自動車株式会社 Solar cell module
NL2017001B1 (en) * 2016-06-20 2018-01-04 Prodrive Tech Bv Sensor system for sensing particle mass concentration in air, splitter unit, dual light beam unit, sensor unit and method for operating the latter
EP3333563A1 (en) * 2016-12-12 2018-06-13 Partanen, Tuomo System and method for determining an amount of fungal particles in air
WO2019147525A1 (en) 2018-01-26 2019-08-01 Advanced Electrofluidic Systems, Llc Method and apparatus for isolating and detecting biological and other particles
US11255794B1 (en) 2018-02-22 2022-02-22 Intelligent Optical Systems, Inc. Multi-substrate passive colorimetric sensors for detecting toxic industrial chemicals and chemical warfare agents
US11011277B1 (en) * 2020-06-02 2021-05-18 Sean Kelly Heat maps of infectious agents and methods of using same to screen subjects and/or determine an infection risk
US20220152614A1 (en) * 2020-11-16 2022-05-19 Koninklijke Fabriek Inventum B.V. Aircraft galley insert with pathogens diagnostic test capabilities
EP4001887A1 (en) * 2020-11-16 2022-05-25 Koninklijke Fabriek Inventum B.V. Methods of obtaining a biological sample representative of a passenger cabin on an aircraft using an air cyclonic collector via a cabin exhaust valve, and systems
CN114045217B (en) * 2022-01-11 2022-04-19 至美时代生物智能科技(北京)有限公司 Air microorganism sampling device and air microorganism sampling and detecting integrated device
CN114594208A (en) * 2022-03-07 2022-06-07 谱瑞前海(深圳)智能科技有限公司 Real-time detection device for virus spread to epidemic disease in air environment

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3241432A (en) * 1962-01-23 1966-03-22 Technicon Instr Method and apparatus for sequentially performing analyses on a plurality of fluid samples
US3604814A (en) * 1969-06-20 1971-09-14 Technicon Corp Method and apparatus for the sequential analysis of fluid samples
US4022575A (en) * 1974-09-16 1977-05-10 Block Engineering, Inc. Automatic chemical analyzer
US4315754A (en) * 1979-08-28 1982-02-16 Bifok Ab Flow injection analysis with intermittent flow
US5589136A (en) * 1995-06-20 1996-12-31 Regents Of The University Of California Silicon-based sleeve devices for chemical reactions
US5741647A (en) * 1996-02-16 1998-04-21 Tam; Joseph Wing On Flow through nucleic acid hybridisation uses thereof and a device thereof
US20020124664A1 (en) * 1998-11-13 2002-09-12 Mesosystems Technology, Inc. Robust system for screening mail for biological agents
US20020187470A1 (en) * 1998-06-24 2002-12-12 Casey Warren Michael Detection of single nucleotide polymorphisms
US20030032172A1 (en) * 2001-07-06 2003-02-13 The Regents Of The University Of California Automated nucleic acid assay system
US20030095897A1 (en) * 2001-08-31 2003-05-22 Grate Jay W. Flow-controlled magnetic particle manipulation
US6586233B2 (en) * 2001-03-09 2003-07-01 The Regents Of The University Of California Convectively driven PCR thermal-cycling
US6688187B1 (en) * 2002-09-10 2004-02-10 The Regents Of The University Of California Aerosol sampling system
US20040038385A1 (en) * 2002-08-26 2004-02-26 Langlois Richard G. System for autonomous monitoring of bioagents
US6699713B2 (en) * 2000-01-04 2004-03-02 The Regents Of The University Of California Polymerase chain reaction system
US6813017B1 (en) * 1999-10-20 2004-11-02 Becton, Dickinson And Company Apparatus and method employing incoherent light emitting semiconductor devices as particle detection light sources in a flow cytometer
US6897031B1 (en) * 1998-04-17 2005-05-24 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in exocytosis
US20070166725A1 (en) * 2006-01-18 2007-07-19 The Regents Of The University Of California Multiplexed diagnostic platform for point-of care pathogen detection

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812370A (en) * 1971-09-07 1974-05-21 Environment One Corp Low cost portable room air cleaner
JPS6146444U (en) * 1984-08-29 1986-03-28 工業技術院長 dust sampler
US5040424A (en) * 1988-07-21 1991-08-20 Regents Of The University Of Minnesota High volume PM10 sampling inlet
JPH05184350A (en) * 1992-01-16 1993-07-27 Mitsubishi Heavy Ind Ltd System for automatic counting of bacterial cell suspending in air
JPH06265447A (en) * 1993-03-16 1994-09-22 Hitachi Ltd Trace quantity reactor and trace element measuring instrument therewith
DE4435107C1 (en) * 1994-09-30 1996-04-04 Biometra Biomedizinische Analy Miniaturized flow thermal cycler
US5861316A (en) * 1994-10-25 1999-01-19 Midwest Research Institute Continuous emission monitoring system
US5716852A (en) * 1996-03-29 1998-02-10 University Of Washington Microfabricated diffusion-based chemical sensor
US6524532B1 (en) * 1995-06-20 2003-02-25 The Regents Of The University Of California Microfabricated sleeve devices for chemical reactions
US5766958A (en) * 1995-09-12 1998-06-16 Sullivan; George D. Method for detecting and collecting infectious airborne microorganisms for rapid identification
US5747349A (en) * 1996-03-20 1998-05-05 University Of Washington Fluorescent reporter beads for fluid analysis
US5968731A (en) 1996-12-10 1999-10-19 The Regents Of The University Of California Apparatus for automated testing of biological specimens
US6122396A (en) * 1996-12-16 2000-09-19 Bio-Tech Imaging, Inc. Method of and apparatus for automating detection of microorganisms
US6235471B1 (en) * 1997-04-04 2001-05-22 Caliper Technologies Corp. Closed-loop biochemical analyzers
US5902385A (en) * 1997-06-23 1999-05-11 Skc, Inc. Swirling aerosol collector
US6368871B1 (en) * 1997-08-13 2002-04-09 Cepheid Non-planar microstructures for manipulation of fluid samples
EP1179585B1 (en) * 1997-12-24 2008-07-09 Cepheid Device and method for lysis
US6369893B1 (en) * 1998-05-19 2002-04-09 Cepheid Multi-channel optical detection system
US6270973B1 (en) * 1998-03-13 2001-08-07 Promega Corporation Multiplex method for nucleic acid detection
US6217636B1 (en) * 1998-03-13 2001-04-17 The Texas A&M University System Transpirated wall aerosol collection system and method
JP3587052B2 (en) * 1998-03-25 2004-11-10 株式会社日立製作所 Biological sample pretreatment method and apparatus therefor
WO1999066304A1 (en) * 1998-06-19 1999-12-23 California Institute Of Technology Trace level detection of analytes using artificial olfactometry
US6908770B1 (en) * 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US6228657B1 (en) * 1998-09-29 2001-05-08 The United States Of America As Represented By The Secretary Of The Army Environmental material ticket reader and airborne hazard detection system
JP3642687B2 (en) * 1998-10-26 2005-04-27 ミドリ安全株式会社 Portable airborne sampler
US5989824A (en) * 1998-11-04 1999-11-23 Mesosystems Technology, Inc. Apparatus and method for lysing bacterial spores to facilitate their identification
US6100084A (en) * 1998-11-05 2000-08-08 The Regents Of The University Of California Micro-sonicator for spore lysis
US6729196B2 (en) * 1999-03-10 2004-05-04 Mesosystems Technology, Inc. Biological individual sampler
US6337213B1 (en) * 1998-12-21 2002-01-08 The Regents Of The University Of California Apparatus and method for collection and concentration of respirable particles into a small fluid volume
US6431476B1 (en) * 1999-12-21 2002-08-13 Cepheid Apparatus and method for rapid ultrasonic disruption of cells or viruses
GB9911336D0 (en) * 1999-05-15 1999-07-14 Graseby Dynamics Ltd Separation and collection of analyte materials
AU782343B2 (en) * 1999-05-28 2005-07-21 Cepheid Apparatus and method for analyzing a fluid sample
US6368870B1 (en) * 1999-06-04 2002-04-09 Hach Company Controlled diffusion analysis
US6468330B1 (en) * 1999-06-14 2002-10-22 Innovatek, Inc. Mini-cyclone biocollector and concentrator
US6471136B1 (en) 1999-06-29 2002-10-29 Carrier Corporation Biosensors for monitoring air conditioning and refrigeration processes
US6491872B1 (en) * 1999-09-17 2002-12-10 The United States Of America As Represented By The Secretary Of The Army Method and system for detecting and recording submicron sized particles
US6777228B2 (en) * 1999-11-08 2004-08-17 Lockheed Martin Corporation System, method and apparatus for the rapid detection and analysis of airborne biological agents
US6403037B1 (en) * 2000-02-04 2002-06-11 Cepheid Reaction vessel and temperature control system
ATE412774T1 (en) * 2000-02-16 2008-11-15 Illumina Inc PARALLEL GENOTYPING OF MULTIPLE PATIENT SAMPLES
US6472018B1 (en) * 2000-02-23 2002-10-29 Howmet Research Corporation Thermal barrier coating method
US6716620B2 (en) * 2000-04-17 2004-04-06 Purdue Research Foundation Biosensor and related method
AU6114501A (en) * 2000-05-03 2001-11-12 Jen Gau Jr Biological identification system with integrated sensor chip
EP1366182A2 (en) * 2000-05-04 2003-12-03 Syngenta Participations AG Assay for nucleic acid analysis
US7682837B2 (en) * 2000-05-05 2010-03-23 Board Of Trustees Of Leland Stanford Junior University Devices and methods to form a randomly ordered array of magnetic beads and uses thereof
WO2001089696A2 (en) * 2000-05-24 2001-11-29 Micronics, Inc. Microfluidic concentration gradient loop
US20020018211A1 (en) * 2000-06-07 2002-02-14 Megerle Clifford A. System and method to detect the presence of a target organism within an air sample using flow cytometry
AU9408801A (en) * 2000-08-07 2002-02-18 Genset Sa Schizophrenia related gene and protein
US6363803B1 (en) * 2000-08-07 2002-04-02 Elmer Hubers Vehicle mounted soil sampler
US6374684B1 (en) * 2000-08-25 2002-04-23 Cepheid Fluid control and processing system
US6402817B1 (en) * 2000-08-25 2002-06-11 The Regents Of The University Of California Low pressure drop, multi-slit virtual impactor
US6787104B1 (en) * 2000-09-14 2004-09-07 The Regents Of The University Of California Detection and treatment of chemical weapons and/or biological pathogens
US6576459B2 (en) * 2001-03-23 2003-06-10 The Regents Of The University Of California Sample preparation and detection device for infectious agents
US20020182657A1 (en) * 2001-05-30 2002-12-05 Ranger Hubert O. Pathogen detection system for drinking water
US6905885B2 (en) * 2001-06-12 2005-06-14 The Regents Of The University Of California Portable pathogen detection system
AU2002334725A1 (en) * 2001-09-28 2003-04-07 Robert B. Silver Makrophage-based biosensor for detection of toxic substances
US6610977B2 (en) * 2001-10-01 2003-08-26 Lockheed Martin Corporation Security system for NBC-safe building
US20040028561A1 (en) * 2001-11-09 2004-02-12 Lockheed Martin Corporation System for the detection of pathogens in the mail stream
US7312071B2 (en) * 2001-12-06 2007-12-25 Arbor Vita Corporation Effective monitoring system for anthrax smallpox, or other pathogens
US6520034B1 (en) * 2002-04-03 2003-02-18 The Regents Of The University Of California High air volume to low liquid volume aerosol collector
US7194924B2 (en) * 2002-07-31 2007-03-27 Lockheed Martin Corporation System and method for biohazard detection using compression

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3241432A (en) * 1962-01-23 1966-03-22 Technicon Instr Method and apparatus for sequentially performing analyses on a plurality of fluid samples
US3604814A (en) * 1969-06-20 1971-09-14 Technicon Corp Method and apparatus for the sequential analysis of fluid samples
US4022575A (en) * 1974-09-16 1977-05-10 Block Engineering, Inc. Automatic chemical analyzer
US4315754A (en) * 1979-08-28 1982-02-16 Bifok Ab Flow injection analysis with intermittent flow
US5589136A (en) * 1995-06-20 1996-12-31 Regents Of The University Of California Silicon-based sleeve devices for chemical reactions
US5741647A (en) * 1996-02-16 1998-04-21 Tam; Joseph Wing On Flow through nucleic acid hybridisation uses thereof and a device thereof
US6897031B1 (en) * 1998-04-17 2005-05-24 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in exocytosis
US20020187470A1 (en) * 1998-06-24 2002-12-12 Casey Warren Michael Detection of single nucleotide polymorphisms
US20020124664A1 (en) * 1998-11-13 2002-09-12 Mesosystems Technology, Inc. Robust system for screening mail for biological agents
US6813017B1 (en) * 1999-10-20 2004-11-02 Becton, Dickinson And Company Apparatus and method employing incoherent light emitting semiconductor devices as particle detection light sources in a flow cytometer
US6699713B2 (en) * 2000-01-04 2004-03-02 The Regents Of The University Of California Polymerase chain reaction system
US6586233B2 (en) * 2001-03-09 2003-07-01 The Regents Of The University Of California Convectively driven PCR thermal-cycling
US20030032172A1 (en) * 2001-07-06 2003-02-13 The Regents Of The University Of California Automated nucleic acid assay system
US20030095897A1 (en) * 2001-08-31 2003-05-22 Grate Jay W. Flow-controlled magnetic particle manipulation
US20040038385A1 (en) * 2002-08-26 2004-02-26 Langlois Richard G. System for autonomous monitoring of bioagents
US6688187B1 (en) * 2002-09-10 2004-02-10 The Regents Of The University Of California Aerosol sampling system
US20070166725A1 (en) * 2006-01-18 2007-07-19 The Regents Of The University Of California Multiplexed diagnostic platform for point-of care pathogen detection

Cited By (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080253294A1 (en) * 2001-12-14 2008-10-16 Alberto Alessandro Della Ripa Data link fault tolerance
US8418129B1 (en) 2001-12-14 2013-04-09 Qualcomm Incorporated Method for automatically generating code to define a system of hardware elements
US7965624B2 (en) 2001-12-14 2011-06-21 Qualcomm Incorporated Data link fault tolerance
US7889729B2 (en) 2001-12-20 2011-02-15 Qualcomm Incorporated System and method for reevaluating granted arbitrated bids
USRE45539E1 (en) 2003-03-14 2015-06-02 Lawrence Livermore National Security, Llc Method for chemical amplification based on fluid partitioning in an immiscible liquid
USRE48788E1 (en) 2003-03-14 2021-10-26 Lawrence Livermore National Security, Llc Chemical amplification based on fluid partitioning
USRE46322E1 (en) 2003-03-14 2017-02-28 Lawrence Livermore National Security, Llc Method for chemical amplification based on fluid partitioning in an immiscible liquid
USRE47080E1 (en) 2003-03-14 2018-10-09 Lawrence Livermore National Security, Llc Chemical amplification based on fluid partitioning
USRE43365E1 (en) 2003-03-14 2012-05-08 Lawrence Livermore National Security, Llc Apparatus for chemical amplification based on fluid partitioning in an immiscible liquid
USRE41780E1 (en) 2003-03-14 2010-09-28 Lawrence Livermore National Security, Llc Chemical amplification based on fluid partitioning in an immiscible liquid
US20070292889A1 (en) * 2006-06-16 2007-12-20 The Regents Of The University Of California Immunoassay magnetic trapping device
US7705739B2 (en) 2006-08-24 2010-04-27 Microfluidic Systems, Inc. Integrated airborne substance collection and detection system
US7633606B2 (en) 2006-08-24 2009-12-15 Microfluidic Systems, Inc. Integrated airborne substance collection and detection system
US20080048874A1 (en) * 2006-08-24 2008-02-28 Microfluidic Systems, Inc. Integrated airborne substance collection and detection system
US7858366B2 (en) 2006-08-24 2010-12-28 Microfluidic Systems, Inc Integrated airborne substance collection and detection system
US20100050742A1 (en) * 2006-08-24 2010-03-04 Microfluidic Systems, Inc. Integrated airborne substance collection and detection system
US8338166B2 (en) 2007-01-04 2012-12-25 Lawrence Livermore National Security, Llc Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture
US20080166793A1 (en) * 2007-01-04 2008-07-10 The Regents Of The University Of California Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture
US7412356B1 (en) 2007-01-30 2008-08-12 Lawrence Livermore National Security, Llc Detection and quantification system for monitoring instruments
US20080183433A1 (en) * 2007-01-30 2008-07-31 The Regents Of The University Of California Detection and quantification system for monitoring instruments
WO2009111072A1 (en) * 2008-03-05 2009-09-11 Clean Earth Technologies, Llc Multiplexed pcr-coupled pna labeled beads flow cytometric assay for simultaneous detection of multiple biological agents
WO2010009426A2 (en) * 2008-07-17 2010-01-21 Life Technologies Corporation Devices and methods for reagent delivery
WO2010009426A3 (en) * 2008-07-17 2010-04-01 Life Technologies Corporation Devices and methods for reagent delivery
US8133451B2 (en) 2008-08-28 2012-03-13 Microfluidic Systems, Inc. Sample preparation apparatus
US20100050749A1 (en) * 2008-08-28 2010-03-04 MicroFluidic Systems, Ltd. Sample preparation apparatus
US9132394B2 (en) 2008-09-23 2015-09-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US9248417B2 (en) 2008-09-23 2016-02-02 Bio-Rad Laboratories, Inc. System for droplet-based assays using an array of emulsions
US8633015B2 (en) 2008-09-23 2014-01-21 Bio-Rad Laboratories, Inc. Flow-based thermocycling system with thermoelectric cooler
US10279350B2 (en) 2008-09-23 2019-05-07 Bio-Rad Laboratories, Inc. Method of generating droplets
US9126160B2 (en) 2008-09-23 2015-09-08 Bio-Rad Laboratories, Inc. System for forming an array of emulsions
US10512910B2 (en) 2008-09-23 2019-12-24 Bio-Rad Laboratories, Inc. Droplet-based analysis method
US9156010B2 (en) 2008-09-23 2015-10-13 Bio-Rad Laboratories, Inc. Droplet-based assay system
US9764322B2 (en) 2008-09-23 2017-09-19 Bio-Rad Laboratories, Inc. System for generating droplets with pressure monitoring
US9216392B2 (en) 2008-09-23 2015-12-22 Bio-Rad Laboratories, Inc. System for forming an array of emulsions
US11130128B2 (en) 2008-09-23 2021-09-28 Bio-Rad Laboratories, Inc. Detection method for a target nucleic acid
US9243288B2 (en) 2008-09-23 2016-01-26 Bio-Rad Laboratories, Inc. Cartridge with lysis chamber and droplet generator
US11612892B2 (en) 2008-09-23 2023-03-28 Bio-Rad Laboratories, Inc. Method of performing droplet-based assays
US11130134B2 (en) 2008-09-23 2021-09-28 Bio-Rad Laboratories, Inc. Method of performing droplet-based assays
US10258988B2 (en) 2008-09-23 2019-04-16 Bio-Rad Laboratories, Inc. Device for generating droplets
US10258989B2 (en) 2008-09-23 2019-04-16 Bio-Rad Laboratories, Inc. Method of making a device for generating droplets
US9417190B2 (en) 2008-09-23 2016-08-16 Bio-Rad Laboratories, Inc. Calibrations and controls for droplet-based assays
US9492797B2 (en) 2008-09-23 2016-11-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US9649635B2 (en) 2008-09-23 2017-05-16 Bio-Rad Laboratories, Inc. System for generating droplets with push-back to remove oil
US11633739B2 (en) 2008-09-23 2023-04-25 Bio-Rad Laboratories, Inc. Droplet-based assay system
US9636682B2 (en) 2008-09-23 2017-05-02 Bio-Rad Laboratories, Inc. System for generating droplets—instruments and cassette
US9623384B2 (en) 2008-09-23 2017-04-18 Bio-Rad Laboratories, Inc. System for transporting emulsions from an array to a detector
US10166522B2 (en) 2009-09-02 2019-01-01 Bio-Rad Laboratories, Inc. System for mixing fluids by coalescence of multiple emulsions
US10677693B2 (en) 2009-09-02 2020-06-09 Bio-Rad Laboratories, Inc. System for mixing fluids by coalescence of multiple emulsions
US9194861B2 (en) 2009-09-02 2015-11-24 Bio-Rad Laboratories, Inc. Method of mixing fluids by coalescence of multiple emulsions
US11866771B2 (en) 2010-03-02 2024-01-09 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US9598725B2 (en) 2010-03-02 2017-03-21 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US11060136B2 (en) 2010-03-02 2021-07-13 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US8709762B2 (en) 2010-03-02 2014-04-29 Bio-Rad Laboratories, Inc. System for hot-start amplification via a multiple emulsion
US10378048B2 (en) 2010-03-02 2019-08-13 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US10744506B2 (en) 2010-03-25 2020-08-18 Bio-Rad Laboratories, Inc. Device for generating droplets
US10099219B2 (en) 2010-03-25 2018-10-16 Bio-Rad Laboratories, Inc. Device for generating droplets
US9500664B2 (en) 2010-03-25 2016-11-22 Bio-Rad Laboratories, Inc. Droplet generation for droplet-based assays
US9393560B2 (en) 2010-03-25 2016-07-19 Bio-Rad Laboratories, Inc. Droplet transport system for detection
US10272432B2 (en) 2010-03-25 2019-04-30 Bio-Rad Laboratories, Inc. Device for generating droplets
US8730479B2 (en) 2010-03-25 2014-05-20 Bio-Rad Laboratories, Inc. Detection system for droplet-based assays
US10619196B1 (en) 2010-04-05 2020-04-14 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10996219B2 (en) 2010-04-05 2021-05-04 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10480022B2 (en) 2010-04-05 2019-11-19 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10612079B2 (en) 2010-04-05 2020-04-07 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10472669B2 (en) 2010-04-05 2019-11-12 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10662467B2 (en) 2010-04-05 2020-05-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10662468B2 (en) 2010-04-05 2020-05-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11866770B2 (en) 2010-04-05 2024-01-09 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11767550B2 (en) 2010-04-05 2023-09-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11761030B2 (en) 2010-04-05 2023-09-19 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11732292B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays correlating target nucleic acid to tissue section location
US11733238B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10914730B2 (en) 2010-04-05 2021-02-09 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11634756B2 (en) 2010-04-05 2023-04-25 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10962532B2 (en) 2010-04-05 2021-03-30 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10961566B2 (en) 2010-04-05 2021-03-30 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10983113B2 (en) 2010-04-05 2021-04-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10982268B2 (en) 2010-04-05 2021-04-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11371086B2 (en) 2010-04-05 2022-06-28 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11001878B1 (en) 2010-04-05 2021-05-11 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11001879B1 (en) 2010-04-05 2021-05-11 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11008607B2 (en) 2010-04-05 2021-05-18 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11560587B2 (en) 2010-04-05 2023-01-24 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11549138B2 (en) 2010-04-05 2023-01-10 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11067567B2 (en) 2010-04-05 2021-07-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11542543B2 (en) 2010-04-05 2023-01-03 Prognosys Biosciences, Inc. System for analyzing targets of a tissue section
US11365442B2 (en) 2010-04-05 2022-06-21 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11384386B2 (en) 2010-04-05 2022-07-12 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11156603B2 (en) 2010-04-05 2021-10-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11519022B2 (en) 2010-04-05 2022-12-06 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11208684B2 (en) 2010-04-05 2021-12-28 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11479810B1 (en) 2010-04-05 2022-10-25 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11293917B2 (en) 2010-04-05 2022-04-05 Prognosys Biosciences, Inc. Systems for analyzing target biological molecules via sample imaging and delivery of probes to substrate wells
US11401545B2 (en) 2010-04-05 2022-08-02 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11313856B2 (en) 2010-04-05 2022-04-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10494667B2 (en) 2010-04-05 2019-12-03 Prognosys Biosciences, Inc. Spatially encoded biological assays
US9089844B2 (en) 2010-11-01 2015-07-28 Bio-Rad Laboratories, Inc. System for forming emulsions
US9222128B2 (en) 2011-03-18 2015-12-29 Bio-Rad Laboratories, Inc. Multiplexed digital assays with combinatorial use of signals
US11352659B2 (en) 2011-04-13 2022-06-07 Spatial Transcriptomics Ab Methods of detecting analytes
US11479809B2 (en) 2011-04-13 2022-10-25 Spatial Transcriptomics Ab Methods of detecting analytes
US11795498B2 (en) 2011-04-13 2023-10-24 10X Genomics Sweden Ab Methods of detecting analytes
US11788122B2 (en) 2011-04-13 2023-10-17 10X Genomics Sweden Ab Methods of detecting analytes
US10190115B2 (en) 2011-04-25 2019-01-29 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US9347059B2 (en) 2011-04-25 2016-05-24 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US9885034B2 (en) 2011-04-25 2018-02-06 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US10760073B2 (en) 2011-04-25 2020-09-01 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US8951939B2 (en) 2011-07-12 2015-02-10 Bio-Rad Laboratories, Inc. Digital assays with multiplexed detection of two or more targets in the same optical channel
US8663920B2 (en) 2011-07-29 2014-03-04 Bio-Rad Laboratories, Inc. Library characterization by digital assay
US9399215B2 (en) 2012-04-13 2016-07-26 Bio-Rad Laboratories, Inc. Sample holder with a well having a wicking promoter
WO2014058486A1 (en) 2012-06-25 2014-04-17 Diagnostic Consulting Network, Inc. Kits and methods for cyanide detection
US11359228B2 (en) 2013-06-25 2022-06-14 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11286515B2 (en) 2013-06-25 2022-03-29 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11753674B2 (en) 2013-06-25 2023-09-12 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11046996B1 (en) 2013-06-25 2021-06-29 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
EP4219745A2 (en) 2013-06-25 2023-08-02 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
EP4234716A2 (en) 2013-06-25 2023-08-30 Prognosys Biosciences, Inc. Methods for determining spatial patterns of biological targets in a sample
US10774372B2 (en) 2013-06-25 2020-09-15 Prognosy s Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11821024B2 (en) 2013-06-25 2023-11-21 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US10927403B2 (en) 2013-06-25 2021-02-23 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11618918B2 (en) 2013-06-25 2023-04-04 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11390912B2 (en) 2015-04-10 2022-07-19 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11613773B2 (en) 2015-04-10 2023-03-28 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11162132B2 (en) 2015-04-10 2021-11-02 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11739372B2 (en) 2015-04-10 2023-08-29 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11299774B2 (en) 2015-04-10 2022-04-12 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US10774374B2 (en) 2015-04-10 2020-09-15 Spatial Transcriptomics AB and Illumina, Inc. Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11624086B2 (en) 2020-05-22 2023-04-11 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
US11866767B2 (en) 2020-05-22 2024-01-09 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity

Also Published As

Publication number Publication date
US9052255B2 (en) 2015-06-09
AU2003304254A1 (en) 2005-01-13
WO2005001435A3 (en) 2005-08-11
US20040038385A1 (en) 2004-02-26
EP1576353A2 (en) 2005-09-21
US20110027781A1 (en) 2011-02-03
AU2003304254B2 (en) 2008-11-20
US20060057599A1 (en) 2006-03-16
WO2005001435A2 (en) 2005-01-06
JP2006508371A (en) 2006-03-09
CA2496128A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
US20050239192A1 (en) Hybrid automated continuous nucleic acid and protein analyzer using real-time PCR and liquid bead arrays
US20030032172A1 (en) Automated nucleic acid assay system
RU2559541C2 (en) Universal system for sample preparing and application in integrated system of analysis
EP3132073B1 (en) Portable nucleic acid analysis system and high-performance microfluidic electroactive polymer actuators
CN100503838C (en) Microflow system for analyzing nucleic acid
Chen et al. An integrated, self-contained microfluidic cassette for isolation, amplification, and detection of nucleic acids
CN101990516B (en) Multiplex sample preparation system and the use in integrated analysis system thereof
EP3081301B1 (en) Apparatus and methods for integrated sample preparation, reaction and detection
US8189186B2 (en) Signal enhancement using a switchable magnetic trap
US20090011417A1 (en) Testing Device
US20030190608A1 (en) Microfluidic devices comprising biochannels
US20070172835A1 (en) Multiplex detection of respiratory pathogens
JPH07506258A (en) Polynucleotide amplification analysis using microfabrication equipment
US20060281101A1 (en) Biobriefcase
US8808643B1 (en) Fluidics platform and method for sample preparation and analysis
US10648023B2 (en) Systems and methods for sampling of amplification products
CN111378573A (en) Micro-pipeline nucleic acid amplification system
McMillan et al. Application of advanced microfluidics and rapid PCR to analysis of microbial targets
EP2785460B1 (en) Systems and methods for sampling of amplification products
Gärtner et al. A microfluidic toolbox approach to CBRNE sensing
Hagan et al. Development of an Automated Microfluidic System for DNA Collection, Amplification, and Detection of Pathogens

Legal Events

Date Code Title Description
AS Assignment

Owner name: ENERGY, U.S. DEPARTMENT OF, DISTRICT OF COLUMBIA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE;REEL/FRAME:017032/0961

Effective date: 20050928

AS Assignment

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CALIF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NASARABADI, SHANAVAZ L.;LANGLOIS, RICHARD G.;COLSTON JR., BILLY W.;AND OTHERS;REEL/FRAME:018562/0178;SIGNING DATES FROM 20050729 TO 20060606

AS Assignment

Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, CALIFOR

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE;REEL/FRAME:020012/0032

Effective date: 20070924

Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC,CALIFORN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE;REEL/FRAME:020012/0032

Effective date: 20070924

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION